Exhibit 10.9


 


SUBSCRIPTION AGREEMENT


 


This Subscription Agreement (this “Agreement”)
has been entered into by and between the purchaser set forth on the Omnibus Signature Page hereof (the “Purchaser”)
and Malo Holdings Corporation (to be renamed “Augmedix, Inc.” upon consummation of the Merger (as defined below)),
a Delaware corporation (the “Company”) in connection with the private placement offering (the “Offering”)
by the Company.


 


R E C I T A L S


 


A. The Company is
offering a minimum of 6,666,667 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”),
at a purchase price of $3.00 per share (the “Per Share Purchase Price”), for an aggregate purchase price
of approximately $20,000,000 (the “Minimum Offering Amount”), and a maximum of 10,000,000 shares of Common
Stock at the Per Share Purchase Price for an aggregate purchase price of approximately $30,000,000 (the “Maximum Offering
Amount”). The Company may also sell an additional 1,666,667 shares of Common Stock at the Per Share Purchase Price
for an aggregate Purchase Price of approximately $5,000,000 to cover over-subscriptions (the “Over-Subscription Option”),
in the event the Offering is oversubscribed.


 


B. The Initial Closing
(as defined below) of no less than the Minimum Offering Amount, including the Minimum Insider Investment (as defined below) is
contingent upon, and shall be consummated simultaneously with, the closing of a merger in accordance with the terms of that certain
Agreement and Plan of Merger, dated as of the date hereof (the “Merger Agreement”), by and among the
Company, Augmedix Acquisition Co., a Delaware corporation (“Merger-Sub”) and wholly owned Subsidiary
of the Company, and Augmedix, Inc., a Delaware corporation (to be renamed “Augmedix Operating Corporation” upon consummation
of the Merger (“Augmedix”), pursuant to which Merger-Sub will merge with and into Augmedix, with Augmedix
surviving the merger as a wholly owned Subsidiary of the Company (the “Merger”), and pursuant to which
all of the outstanding stock of Augmedix will be cancelled in exchange for shares of the Company’s Common Stock, and all
outstanding Augmedix options, stock appreciation rights and warrants will be assumed by the Company, at the same ratio at which
outstanding stock of Augmedix are exchanged, with appropriate adjustments to the per share exercise price thereof, and otherwise
on their original terms and conditions. The total number of shares of the Company’s Common Stock that will be issued to pre-Merger
stockholders of Augmedix or reserved for issuance upon exercise of pre-Merger options, stock appreciation rights and warrants of
Augmedix is expected to be 22,937,294 shares. In addition, as of the Closing, the Company will have an Equity Incentive Plan (the
“EIP”) reserving 437,653 shares of Common Stock, covering pre-Merger Augmedix options to be assumed by,
or exchanged for options of, the Company, as well as for the future issuance, at the discretion of the Board of Directors, of options
and other incentive awards to officers, key employees, consultants and directors of the Company and its Subsidiaries. The number
of shares initially reserved for issuance under the EIP will be increased annually on the first day of each year beginning in 2021,
at the discretion of the Board, in an amount up to five percent (5%) of the shares of stock outstanding (on an as-converted basis)
on the last day of the immediately preceding year. Holders of Common Stock of the Company prior to the Merger will retain in the
aggregate 2,166,667 shares of Common Stock after the Merger. On or before the consummation of the Merger, the Company will change
its name to “Augmedix, Inc.,” and Augmedix will change its name to a name to be determined.


 




    1


     


    

 


C. The
Shares (as defined below) subscribed for pursuant to this Agreement have not been registered under the Securities Act of 1933,
as amended, and the rules and regulations promulgated thereunder (the “Securities Act”) or any state
or foreign securities Law. The Offering is being made on a reasonable best efforts basis to “accredited investors,”
as defined in Regulation D under the Securities Act, in reliance upon the exemption from securities registration afforded by Section
4(a)(2) of the Securities Act and Rule 506 of Regulation D. For purposes of this Agreement, “Law” or
“Laws” means any federal, state, local or foreign or provincial statute, law (including, for the avoidance
of doubt, any statutory, common, or civil law), ordinance, rule, regulation, order, injunction, decree or agency requirement having
the force of law or any undertaking to or agreement with any Governmental Authority (as defined below).


 


D. The
parties intend to treat the Merger, together with the Initial Closing and the Subsequent Closing, if relevant, as part of a transaction
that is described in Section 351(a) of the Internal Revenue Code of 1986, as amended (the “Code”) to
the extent property is exchanged for stock as described therein.


 


AGREEMENT


 


The Company and the Purchaser hereby agree as follows:


 


		1.	Subscription.



 


		(a)	Purchase and Sale of the Shares.



 


(i) Subject
to the terms and conditions of this Agreement, the Purchaser agrees to purchase, and the Company agrees to sell and issue to the
Purchaser, that number of Shares set forth on the Purchaser’s Omnibus Signature Page attached hereto at the Per Share Purchase
Price, for a total aggregate purchase price for the Shares as set forth on such Omnibus Signature Page (the “Purchase
Price”). The minimum subscription amount for each purchaser in the Offering is $24,999 (or 8,333 Shares). The Company
may accept subscriptions for less than $24,999 from any purchaser in the Offering in its sole discretion. Current officers, directors,
stockholders of Augmedix and their respective friends and family (“Insider Investors”) will purchase
a minimum aggregate amount of $10,000,000 of Shares in the Offering (the “Minimum Insider Investment”).
For the purposes of this Agreement, “Shares” means the shares of Common Stock issued and sold to the
Purchaser hereunder in the Offering at the Initial Closing (as defined below) and at any Subsequent Closing (as defined below).


 


(ii) In
connection with the Offering, the Company has entered or will enter into other subscription agreements in the same form and containing
the same terms and conditions as this Agreement for shares of Common Stock (“Other Shares”) (each, an
“Other Subscription Agreement”) with purchasers in the Offering other than the Purchaser (collectively,
“Other Purchasers”).


 






    2


     


    

 


		(b)	Subscription Procedure; Closing.



 


(i) Initial
Closing. Subject to the terms and conditions of this Agreement, the initial closing of the Offering shall take place upon the
satisfaction (or waiver as provided herein) of the conditions set forth in Section 5 and Section 6 of this Agreement (other than
those conditions that by their nature will be satisfied at the Closing, but subject to the satisfaction (or waiver as provided
herein) of such conditions) or at such other time and place as is mutually agreed to by the Company and the Placement Agents (as
defined below) contingent upon and simultaneously with the closing of the Merger (the “Initial Closing”
and the date that the Initial Closing occurs, the “Initial Closing Date”). The Company shall provide
written notice to the Purchaser of the date of the Initial Closing at least three (3) Business Days prior to the Initial Closing.
For the purposes of this Agreement, “Business Day” means a day, other than a Saturday or Sunday, on which
banks in New York City are open for the general transaction of business.


 


(ii) Subsequent
Closings. If the Maximum Offering Amount is not sold at the Initial Closing, at any time prior to October 30, 2020, or at such
later date as the Company and Placement Agents may mutually agree, without notice to or consent from the Purchaser or any Other
Purchaser, subject to the satisfaction (or waiver as provided herein) of the conditions set forth in Section 5 and Section 6 of
this Agreement (other than those conditions that by their nature will be satisfied at the Closing, but subject to the satisfaction
(or waiver as provided herein) of such conditions) (each a “Subsequent Closing” and collectively the
“Subsequent Closings” and the date that a Subsequent Closing occurs, a “Subsequent Closing
Date”), the Company may sell additional shares of Common Stock up to the Maximum Offering Amount, and if there are
over-subscriptions, additional shares of Common Stock may be sold at the Per Share Purchase Price in connection with the Over-Subscription
Option (collectively, the “Subsequent Closing Shares”) to such persons as may be approved by the Company
and who are reasonably acceptable to the Placement Agents, including the Purchaser. Any Subsequent Closing Shares issued and sold
to the Purchaser pursuant to this Section 1(b)(ii) shall be deemed to be “Shares” for all purposes under
this Agreement. To the extent that any Shares are to be issued and sold to the Purchaser at a Subsequent Closing, the Company shall
provide written notice to the Purchaser of the date of any Subsequent Closing at least three (3) Business Days prior to such Subsequent
Closing.


 


The Initial
Closing and the Subsequent Closings, if any, shall be known collectively herein as the “Closings” or
individually as a “Closing.” The Initial Closing Date and the Subsequent Closing Dates are each referred
to herein as a “Closing Date”. Closings may take place remotely via the exchange by electronic transmission
of documents and signatures


 


(iii) Subscription
Procedure. To complete a subscription for the Shares, the Purchaser must fully comply with the subscription procedure provided
in subparagraphs (A) through (D) of this paragraph (iii) on or before the applicable Closing Date:


 


(A) Subscription
Documents. At or before the applicable Closing, the Purchaser shall review, complete and execute the Omnibus Signature Page
to this Agreement and the Registration Rights Agreement substantially in the form of Exhibit A hereto (the “Registration
Rights Agreement”), the Selling Securityholder Questionnaire (as defined in the Registration Rights Agreement),
the Investor Profile, Anti-Money Laundering Form and Accredited Investor Certification, attached hereto following the Omnibus Signature
Page (collectively, the “Subscription Documents”), and deliver the Subscription Documents to the party
indicated thereon at the address set forth under the caption “How to subscribe for Shares in the private offering of Malo
Holdings Corporation” below. Executed documents may be delivered to such party by facsimile or .pdf sent by electronic
mail (e-mail).


 






    3


     


    

 


(B) Purchase
Price. At or before the applicable Closing, the Purchaser shall deliver to Delaware Trust Company, in its capacity as escrow
agent (the “Escrow Agent”), under an escrow agreement among the Company, Augmedix, the Placement Agents
(as defined below) and the Escrow Agent (the “Escrow Agreement”) the full Purchase Price (less the amount
of any Transaction Expenses, if applicable) set forth on the Purchaser’s Omnibus Signature Page attached hereto, by certified
or other bank check or by wire transfer of immediately available funds, pursuant to the instructions set forth under the caption
“How to subscribe for Shares in the private offering of Malo Holdings Corporation” below. Such funds will be
held for the Purchaser’s benefit in the escrow account established for the Offering (the “Escrow Account”),
without interest or offset.


 


(C) Termination.
This Agreement shall terminate automatically and be of no further force and effect, and any amounts deposited into the Escrow Account
by or on behalf of the Purchaser shall be returned to the Purchaser or its designee promptly, without interest or offset, if (i)
the Purchaser and the Company agree in writing to terminate this Agreement prior to the applicable Closing, (ii) the subscription
has been revoked in full by the Purchaser in accordance with Section 8, (iii) in the Purchaser’s sole and absolute
discretion, upon written notice to the Company, if any representation or warranty of the Company set forth in Section 3
hereof shall be or shall have become inaccurate or the Company shall have breached or failed to perform any of its covenants or
other agreements set forth in this Agreement, which inaccuracy, breach or failure to perform would give rise to the failure to
satisfy any of the conditions set forth in Section 6(a) or Section 6(b) of this Agreement and which inaccuracy, breach
or failure to perform cannot be cured by the Company or, if capable of being cured, is not cured within two (2) Business Days of
the Purchaser’s notice to the Company thereof; or (iv) the Merger Agreement is terminated pursuant to its terms. The Company
shall promptly (and in any event within one (1) Business Day) provide the Purchaser with written notice of the termination of the
Merger Agreement.


 


(D) Company
Discretion. The Purchaser understands and agrees that, prior to the execution and delivery of this Agreement by the Company,
the Company in its sole discretion reserves the right to accept or reject this subscription for Shares, in whole or in part. The
Company and the Purchaser shall have no obligation hereunder until the Company shall execute and deliver to the Purchaser an executed
copy of this Agreement.


 


2. Placement
Agents. Stifel, Nicolaus & Company, Incorporated, B. Riley Securities, Inc. and GP Nurmenkari Inc. (the “Placement
Agents”), each a U.S.-registered broker-dealer, have been engaged by the Company as placement agents, on a reasonable
best efforts basis, for the Offering. The Placement Agents, collectively, will be paid at each Closing from the Offering proceeds
a total cash commission of eight percent (8.0%) of the gross Purchase Price paid by the Purchaser and the gross aggregate purchase
price paid by all Other Purchasers in the Offering (the “Cash Fee”) and will receive non-transferrable
warrants to purchase a number of shares of Common Stock equal to 8% of the number of shares of Common Stock sold in the Offering
other than to Insider Investors, with a term of five years and an exercise price of $3.00 per share (the “Placement
Agent Warrants”). The Company will also pay certain expenses of the Placement Agents in connection with the Offering.
Any sub-agent of the Placement Agent that introduces investors to the Offering will be entitled to share in the Cash Fee and Placement
Agent Warrants attributable to those investors pursuant to the terms of an executed sub-agent agreement.


 






    4


     


    

 


3. Representations
and Warranties of the Company. Except (i) as set forth in the Disclosure Schedule delivered to the Purchaser
concurrently with the execution of this Agreement (the “Disclosure Schedule”), or (ii) as disclosed
in the substantially complete draft of the Current Report on Form 8-K describing the Merger, the Offering and the related
transactions, including “Form 10 information” (as defined in Rule 144(i)(3) under the Securities Act), to be
filed by the Company with the Securities and Exchange Commission (the “SEC”) within four (4)
Business Days (as defined below) after the closing of the Merger and the initial Closing of the Offering (the
“Super 8-K”) delivered to the Purchaser in accordance with the terms of this Agreement (the
“Draft Super 8-K”) (but excluding any disclosures (whether contained under the heading “Risk
Factors,” in any “forward-looking statements” disclaimer or in any other section) to the extent they are
cautionary, predictive or forward-looking in nature), the Company hereby represents and warrants to the Purchaser, as of the
date hereof and as of each applicable Closing Date, the following (provided that, as used in this Section 3, the term
“Subsidiaries” shall be construed to include Augmedix as of each applicable Closing Date):


 


(a) Organization
and Qualification. The Company and each of its Subsidiaries is a corporation or limited liability company, as the case may
be, duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or formation,
and has the requisite corporate or limited liability company power to own, lease and operate its properties and to carry on its
business as currently conducted and as described in the Super 8-K. The Company and each of its Subsidiaries is duly qualified as
a foreign corporation or limited liability company, as the case may be, to do business and is in good standing in every jurisdiction
in which the nature of the business as currently conducted and as described in the Super 8-K makes such qualification necessary,
except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. For purposes
of this Agreement, “Material Adverse Effect” means any event, circumstance, development, condition, occurrence,
state of facts, change or effect that, individually or in the aggregate with any other event, circumstance, development, condition,
occurrence, state of facts, change or effect, has or would reasonably be expected to (x) prevent or materially delay or materially
impair the ability of the Company or its Subsidiaries to carry out its obligations under this Agreement or (y) have any material
adverse effect on the business, properties, assets, liabilities, operations or condition (financial or otherwise), results of operations
or future prospects of the Company and its Subsidiaries, taken as a whole; provided, however, that for purposes of
clause (y), none of the following shall be deemed in themselves, either alone or in combination, to constitute, and none of the
following shall be taken into account in determining whether there has been or would reasonably be expected to have a “Material
Adverse Effect”: (i) general financial, credit, capital market or regulatory conditions or any changes therein (provided,
however, that such effects do not affect the Company and its Subsidiaries taken as a whole disproportionately as compared
to the Company’s competitors), (ii) any effects alone or in combination that arise out of, or result from, directly or indirectly
from the announcement, pendency, execution or performance of this Agreement, the transactions contemplated hereby or any action
contemplated by this Agreement, (iii) acts of God, war (whether or not declared), disease, including the COVID 19 pandemic, the
commencement, continuation or escalation of a war, acts of armed hostility, sabotage or terrorism or other international or national
calamity or any material worsening of such conditions (provided, however, that such changes do not affect the Company
or its Subsidiaries disproportionately as compared to the Company’s competitors), (iv) any matter disclosed in the Disclosure
Schedule or the draft of the Super 8-K (excluding any disclosures (whether contained under the heading “Risk Factors,”
in any “forward looking statements” disclaimer or in any other section) to the extent they are cautionary, predictive
or forward-looking in nature); (v) any failure by the Company or its Subsidiaries to meet any projections, budgets or estimates
of revenue or earnings (it being understood that the facts giving rise to such failure may be taken into account in determining
whether there has been a Material Adverse Effect (except to the extent such facts are otherwise excluded from being taken into
account by this proviso)), (vi) changes affecting the industry generally in which the Company or its Subsidiaries operates (provided,
however, that such changes do not affect the Company or its Subsidiaries disproportionately as compared to the Company’s
competitors), or (vii) changes in Law or GAAP (provided, however, that such changes do not affect the Company or
its Subsidiaries disproportionately as compared to the Company’s competitors). For purposes of this Agreement, “Subsidiary”
means, with respect to the Company, any corporation, partnership, limited liability company, joint venture or other legal entity
of any kind of which (i) 50% or more of the capital stock or other equity interests or voting power are, directly or indirectly,
controlled, owned or held by, or (ii) that is, at the time any determination is made, controlled (whether by voting power, Contract
(as defined below) or otherwise) by, in each case, the Company (either alone or through or together with one or more of its other
Subsidiaries); provided, that for all purposes of the representations and warranties of the Company set forth in this Agreement,
whether made as of the date hereof or as of the applicable Closing Date, Augmedix and its Subsidiaries shall be deemed to be Subsidiaries
of the Company regardless of whether the Merger has been consummated.


 






    5


     


    

 


(b) Authorization,
Enforcement, Compliance with Other Instruments. (i) The Company and each of its Subsidiaries party thereto has the requisite
corporate or limited liability company power and authority to enter into and perform its obligations under this Agreement, the
Registration Rights Agreement, the Escrow Agreement and the Merger Agreement (collectively with all other documents, certificates
or instruments executed and delivered in connection with the transactions contemplated hereby or thereby, the “Transaction
Documents”) and to consummate the transactions contemplated thereby, including to issue the Shares, in accordance
with the terms hereof and thereof; (ii) the execution and delivery by the Company and each of its Subsidiaries party thereto of
each of the Transaction Documents and the consummation by it of the transactions contemplated hereby and thereby, including, without
limitation, the issuance of the Shares, have been, or will be at the time of execution of such Transaction Document, duly authorized
by the Board of Directors or other applicable governing body of the Company or such Subsidiary, and no further action, proceeding,
consent, waiver or authorization is, or will be at the time of execution of each such Transaction Document, required by or from
the Company or any such Subsidiary, its respective Board of Directors or other governing body or its respective stockholders or
equity holders; (iii) this Agreement has been, and at the Closing each of the other Transaction Documents will be when delivered
at the Closing, duly executed and delivered by the Company and each of its Subsidiaries party thereto; and (iv) this Agreement
and the other Transaction Documents, when delivered at the Closing or at the closing of the Merger, as applicable, will constitute
the valid and binding obligations of the Company and its Subsidiaries party thereto enforceable against the Company and its Subsidiaries
party thereto in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement
of creditors’ rights and remedies and, with respect to any rights to indemnity or contribution contained in the Transaction
Documents, as such rights may be limited by state or federal laws or public policy underlying such laws.


 


(c) Capitalization.
As of the date hereof and without giving effect to the Merger, the authorized capital stock of the Company consists of
50,000,000 shares of Common Stock and 5,000,000 shares of preferred stock, par value $0.0001 per share (the
“Preferred Stock”) and there are 5,000,000 shares of Common Stock outstanding and no shares of
Preferred Stock outstanding. Immediately following the effective time of the Merger, but immediately before the Initial
Closing, the authorized capital stock of the Company will consist of 300,000,000 shares of Common Stock and 10,000,000 shares
of Preferred Stock, and the Company is expected to have 17,739,264 shares of Common Stock issued and outstanding and no
shares of Preferred Stock issued and outstanding. All of the outstanding shares of Common Stock and of the capital stock of
each of the Company’s Subsidiaries have been duly authorized, validly issued and are fully paid and non-assessable and
free of preemptive or similar rights and other Liens. All of the issued and outstanding capital stock of each Subsidiary of
the Company are owned, directly or indirectly, by the Company, free and clear of any Liens. Immediately after giving effect
to the Merger and the Closing of the Minimum Offering Amount or the Maximum Offering Amount (in each case, assuming no sales
pursuant to the Over-Subscription Option), the pro forma outstanding capitalization of the Company will be as set forth under
“Pro Forma Capitalization” in Schedule 3c. Immediately after giving effect to the
Merger and the Closing: (i) no shares of capital stock of the Company or any of its Subsidiaries will be subject to
preemptive rights or any other similar rights or any Liens suffered or permitted by the Company; (ii) except as set
forth on Schedule 3c(ii), there will be no outstanding options, warrants, scrip, rights to subscribe to, calls
or commitments of any character whatsoever relating to, or securities or rights convertible, exercisable or exchangeable
into, any shares of capital stock of the Company or any of its Subsidiaries, or any Contracts by which the Company or any of
its Subsidiaries is or may become bound or pursuant to which the Company or any of its Subsidiaries is otherwise obligated to
issue additional shares of capital stock of the Company or any of its Subsidiaries; (iii) there will be no outstanding debt
securities of the Company or any of its Subsidiaries other than indebtedness as set forth in Schedule 3c(iii);
(iv) other than pursuant to the Registration Rights Agreement or as set forth in Schedule 3c(iv), there will be
no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of
their securities under the Securities Act; (v) there will be no outstanding registration statements of the Company or any of
its Subsidiaries, other than pursuant to the Registration Rights Agreement; (vi) except as set forth in Schedule
3c(vi), there will be no securities or instruments of the Company or any of its Subsidiaries containing anti-dilution
or similar provisions, including the right to adjust the exercise, exchange or reset price under such securities, that will
be triggered by the issuance of the Shares as described in this Agreement; (vii) no co-sale right, right of first refusal or
other similar right will exist with respect to the Shares or the issuance and sale thereof and (viii) no shares of Common
Stock shall be reserved for issuance, other than 437,653 shares of Common Stock reserved for issuance under the EIP. The
Company has made available to the Purchaser true and correct copies of the Company’s Certificate of Incorporation, as
in effect as of the Initial Closing, and the Company’s Bylaws, as in effect as of the Initial Closing, and the terms of
all securities exercisable for Common Stock and the material rights of the holders thereof in respect thereto other than
stock options issued to officers, directors, employees and consultants. Except for the interests in the Company’s
Subsidiaries, neither the Company nor any of its Subsidiaries owns any equity interest or other interest of any nature in, or
any interest convertible, exchangeable, or exercisable for, equity interests or other interests of any nature in any other
person.


 






    6


     


    

 


(d) Issuance
of Shares. The Shares that are being issued to the Purchaser hereunder, when issued, sold and delivered in accordance with
the terms and upon payment the consideration set forth in this Agreement, will be duly and validly issued, fully paid and non-assessable,
and free of preemptive or similar rights, Taxes and other Liens with respect to the issuance thereof, and restrictions on transfer
other than restrictions on transfer under the Transaction Documents, applicable state and federal securities Laws and Liens created
by or imposed by the Purchaser. Assuming the accuracy of each of the representations and warranties of the Purchaser herein, the
offer, issuance and sale by the Company of the Shares is exempt from registration under the Securities Act.


 


(e) No
Conflicts. The execution, delivery and performance of each of the Transaction Documents by the Company, and the consummation
by the Company of the transactions contemplated hereby and thereby, including issuance and sale of the Shares in accordance with
this Agreement, have not and will not (i) result in a violation of the Certificate of Incorporation or the Bylaws (or equivalent
constitutive document) of the Company or any of its Subsidiaries; (ii) violate or conflict with, or result in a breach of any provision
of, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others
any rights of termination, amendment, acceleration or cancellation of, any Contract to which the Company or any Subsidiary is a
party, except for those which would not reasonably be expected to be material to the business of the Company and its Subsidiaries,
taken as a whole, or (iii) result in a violation of any Law applicable to the Company or any Subsidiary or by which any property
or asset of the Company or any Subsidiary is bound or affected, except for those which would not reasonably be expected to be material
to the business of the Company and its Subsidiaries, taken as a whole. Neither the Company nor any Subsidiary is in violation of
or in default under, any provision of its Certificate of Incorporation or Bylaws or any other constitutive documents. Neither the
Company nor any Subsidiary is in violation of any term of or in default under any Contract, judgment, decree or order or any Law
applicable to the Company or any Subsidiary, which violation or breach has been or would reasonably be expected to be material
to the business of the Company and its Subsidiaries, taken as a whole. Except as specifically contemplated by this Agreement and
as required under the Securities Act and any applicable state securities Laws, neither the Company nor any of its Subsidiaries
is required to obtain any Authorization of, or provide any notice to or make any filing or registration with, any Governmental
Authority in order for it to execute, deliver or perform any of its obligations under or contemplated by this Agreement or the
other Transaction Documents in accordance with the terms hereof or thereof, other than (i) the filings required pursuant to Section
9(j), (ii) the filing of the registration statement contemplated by the Registration Rights Agreement and (iii) the filing of a
Notice of Exempt Offering of Securities on Form D with the SEC under Regulation D. Except as set forth on Schedule 3e,
neither the execution and delivery by the Company of the Transaction Documents, nor the consummation by the Company of the transactions
contemplated hereby or thereby, will require any notice, consent or waiver under any Contract to which the Company or any Subsidiary
is a party or by which the Company or any Subsidiary is bound or to which any of their assets or businesses is subject, except
for any notice, consent or waiver the absence of which would not reasonably be expected, individually or in the aggregate, to be
material to the business of the Company and its Subsidiaries, taken as a whole. All notices, consents, authorizations, orders,
filings and registrations which the Company or any of its Subsidiaries is required to deliver or obtain pursuant to the preceding
two sentences have been or will be delivered or obtained or effected, and shall remain in full force and effect, on or prior to
the Closing.


 






    7


     


    

 


(f) Absence
of Litigation. Except as set forth on Schedule 3f, there is no, and since the date that is two (2) years prior
to the date hereof (the “Lookback Date”) there has not been any, action, suit, claim, inquiry, notice
of violation, arbitration, petition, charge, citation, summons, subpoena, proceeding (including any partial proceeding such as
a deposition) or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity,
before or by any Governmental Authority (an “Action”) pending or threatened in writing or, to the knowledge
of the Company, threatened orally, against or affecting the Company or any of its Subsidiaries or any of their respective officers
or directors or any of their respective assets or businesses, which has or would be reasonably likely to (i) adversely affect the
validity or enforceability of, or the authority or ability of the Company to perform its obligations under, this Agreement or any
of the other Transaction Documents or (ii) be material to the business of the Company and its Subsidiaries, taken as a whole. For
the purpose of this Agreement, the knowledge of the Company means the knowledge of the officers of the Company (for the avoidance
of doubt, after giving effect to the Merger) and Augmedix, in each case, both actual or knowledge that they would have had upon
reasonable inquiry of the personnel of the Company or Augmedix, as applicable responsible for the applicable subject matter. Neither
the Company nor any of its Subsidiaries is, and since the Lookback Date has not been, subject to any judgment, decree, or order
which has been, or would reasonably be expected to be material to the business of the Company and its Subsidiaries, taken as a
whole.


 


(g) Acknowledgment
Regarding Purchaser’s Purchase of the Shares. The Company acknowledges and agrees that the Purchaser is acting solely
in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
hereby and thereby. The Company further acknowledges that the Purchaser are not acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any
advice given by the Purchaser or any of its representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchaser’s purchase of the Shares.


 


(h) No
General Solicitation. Neither the Company, nor any of its Affiliates (as defined below), nor, to the knowledge of the Company,
any person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning
of Regulation D) in connection with the offer or sale of the Shares. “Affiliate” means, with respect
to any person, any other person that, directly or indirectly through one or more intermediaries, controls, is controlled by or
is under common control with such person, as such terms are used in and construed under Rule 144 under the Securities Act (“Rule
144”). With respect to the Purchaser, any investment fund or managed account that is managed on a discretionary basis
by the same investment manager as the Purchaser will be deemed to be an Affiliate of the Purchaser.


 


(i) No
Integrated Offering. Neither the Company, nor any of its Affiliates, nor to the knowledge of the Company, any person acting
on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any
security, under circumstances that would eliminate the availability of the exemption from registration under Regulation D or afforded
by Section 4(a)(2) of the Securities Act in connection with the Offering of the Shares contemplated hereby or cause this Offering
of the Shares to be integrated with prior offerings by the Company for purposes of the Securities Act.


 


(j) Employee
Relations. Since the Lookback Date, there has been no actual or threatened in writing, or to the knowledge of the Company,
threatened orally, labor dispute, work stoppage, request for representation, union organizing activity, or unfair labor practice
charges involving the employees of the Company or any of its Subsidiaries. Neither Company nor any Subsidiary is party to any collective
bargaining agreement. The Company’s and/or its Subsidiaries’ employees are not members of any union, and the Company
believes that its and its Subsidiaries’ relationship with their respective employees is good.


 






    8


     


    

 


(k) Intellectual
Property Rights. Except as set forth on Schedule 3k, the Company and each of its Subsidiaries exclusively owns,
possesses, or has valid and enforceable rights to use, license, and exploit all Intellectual Property used in, necessary or advisable
for the conduct of the Company’s and its Subsidiaries’ business as currently conducted and as described in the Super
8-K, except for a failure to own, possess or have such rights that would not reasonably be expected to result in a Material Adverse
Effect. There are no unreleased liens or security interests which have been filed, or which the Company has received notice of,
against any of the Intellectual Property owned by the Company. All Intellectual Property owned by the Company or its Subsidiaries,
and all Contracts pursuant to which the Company or its Subsidiaries license Intellectual Property, are valid and enforceable, and
the Company and its Subsidiaries are in full compliance with all such Contracts except as would not reasonably be expected to result
in a Material Adverse Effect. Furthermore, except as has not been and would not reasonably be expected to result in a Material
Adverse Effect, since the Lookback Date: (A) to the Company’s knowledge, there has been no infringement, misappropriation
or violation by third parties of any such Intellectual Property of the Company or its Subsidiaries; (B) there has been no Action
pending or threatened in writing (or to the Company’s knowledge, threatened orally) by others challenging the Company’s
or any of its Subsidiaries’ ownership of or any rights in or to any such Intellectual Property; (C) the Intellectual Property
owned by the Company and its Subsidiaries and, to the Company’s knowledge, the Intellectual Property licensed to the Company
and its Subsidiaries, has not been adjudged invalid or unenforceable, in whole or in part, and there has been no Action pending
or threatened in writing (or to the Company’s knowledge, threatened orally) by others challenging the validity, enforceability
or scope of any such Intellectual Property; (D) there has been no Action pending or threatened in writing (or to the Company’s
knowledge, threatened orally) by others that the Company or any of its Subsidiaries infringes, misappropriates or otherwise violates
any Intellectual Property or other proprietary rights of others, and neither the Company nor any of its Subsidiaries has received
any written notice of such Action; and (E) to the Company’s knowledge, no employee of the Company or any of its Subsidiaries
has violated any term of any employment Contract, patent disclosure agreement, invention assignment agreement, non-competition
agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the
basis of such violation relates to such employee’s employment with the Company or any of its Subsidiaries or actions undertaken
by the employee while employed with the Company or any of its Subsidiaries. The Company and its Subsidiaries have complied in all
material respects with 37 C.F.R. Section 1.56. The consummation of the transactions contemplated hereby or by the other Transaction
Documents will not result in the loss or impairment of or payment of any additional amounts with respect to, nor require the consent
of any other person in respect of, the Company or any of its Subsidiaries’ right to own, use or hold for use any Intellectual
Property as owned, used or held for use in the conduct of the Company’s and its Subsidiaries’ business as currently
conducted and as described in the Super 8-K, except as would not reasonably be expected to be material to the business of the Company
and its Subsidiaries, taken as a whole. The rights of the Company and each of its Subsidiaries in their Intellectual Property are
valid, subsisting and enforceable, except as would not reasonably be expected to be material to the business of the Company and
its Subsidiaries, taken as a whole. The Company and each of its Subsidiaries has taken reasonable steps to maintain their Intellectual
Property and to protect and preserve the confidentiality of all of their Trade Secrets. To the Company’s knowledge, there
has not been any disclosure or access to any Trade Secrets of the Company and each of its Subsidiaries by any unauthorized person.
The Company and each of its Subsidiaries have taken and continue to take commercially reasonable measures, at least consistent
with prevailing industry practice, to ensure that all personal information in their possession, custody or control is protected
against loss and against unauthorized, access, use, modification, disclosure or other misuse. “Intellectual Property”
shall mean any and all rights title and interest in, arising out of, or associated with any intellectual or intangible property,
whether protected, created or arising in any jurisdiction throughout the world, including the following: (a) issued patents and
patent applications (whether provisional or non-provisional), including divisionals, continuations, continuations-in-part, substitutions,
reissues, reexaminations, extensions, or restorations of any of the foregoing, and other Governmental Authority issued indicia
of invention ownership (including certificates of invention, petty patents, and patent utility models) (“Patents”);
(b) trademarks, service marks, brands, certification marks, logos, trade dress, slogans, trade names, and other similar indicia
of source or origin, together with the goodwill connected with the use of and symbolized by, and all registrations, applications
for registration, and renewals of, any of the foregoing (“Trademarks”); (c) copyrights and works of authorship,
whether or not copyrightable, and all registrations, applications for registration, and renewals of any of the foregoing (“Copyrights”);
(d) internet domain names and social media account or user names (including “handles”), whether or not
Trademarks, all associated web addresses, URLs, websites and web pages, social media sites and pages, and all content and data
thereon or relating thereto, whether or not Copyrights; (e) mask works, and all registrations, applications for registration, and
renewals thereof; (f) industrial designs, and all Patents, registrations, applications for registration, and renewals thereof;
(g) trade secrets, know-how, inventions (whether or not patentable), discoveries, improvements, technology, business and technical
information, databases, data compilations and collections, tools, methods, processes, techniques, and other confidential and proprietary
information and all rights therein (“Trade Secrets”); (h) computer programs, operating systems, applications,
firmware and other code, including all source code, object code, application programming interfaces, data files, databases, protocols,
specifications, and other documentation thereof; (i) rights of publicity; and (j) all other intellectual or industrial property
and proprietary rights.


 






    9


     


    

 


(l)
Environmental Laws.


 


(i) Except
as would not reasonably be expected to be material to the business of the Company and its Subsidiaries, taken as a whole: (x)
the Company and each Subsidiary is in compliance and has complied with all applicable Environmental Laws (as defined below); (y)
the Company or its applicable Subsidiary is in possession of all Authorizations required pursuant to Environmental Laws to conduct
their respective businesses as currently conducted and as described in the Super 8-K and (z) the Company or its applicable Subsidiary
is in material compliance with all terms and conditions of such Authorizations. There is no Action pending or threatened in writing
(or to the Company’s knowledge, threatened orally) relating to any violation or noncompliance with any Environmental Law
involving the Company or any Subsidiary. For purposes of this Agreement, “Environmental Law” means any
national, state, provincial or local Law, statute, rule or regulation or the common law relating to the environment or occupational
health and safety, including without limitation any statute, regulation, administrative decision or order pertaining to (A) treatment,
storage, disposal, generation and transportation of Hazardous Substances; (B) air, water and noise pollution; (C) groundwater
and soil contamination; (D) the release or threatened release into the environment of industrial, toxic or hazardous materials
or substances, or solid or hazardous waste, including without limitation emissions, discharges, injections, spills, escapes or
dumping of pollutants, contaminants or chemicals; (E) the protection of wild life, marine life and wetlands, including without
limitation all endangered and threatened species; (F) storage tanks, vessels, containers, abandoned or discarded barrels, and
other closed receptacles; (G) health and safety of employees and other persons; and (H) manufacturing, processing, using, distributing,
treating, storing, disposing, transporting or handling of Hazardous Substances. As used above, the terms “release”
and “environment” shall have the meaning set forth in the Comprehensive Environmental Response, Compensation and Liability
Act of 1980, as amended.


 


(ii) None
of the Company or any of its Subsidiaries has any liability or obligation under any Environmental Law with respect to any release,
spill, emission, leaking, pumping, pouring, emptying, leaching, escaping, dumping, injection, deposit, discharge or disposing of
any Hazardous Substance in, onto or through the environment, except as would not reasonably be expected to have a Material Adverse
Effect. “Hazardous Substances” means all materials, wastes, or substances defined by, or regulated under,
any Environmental Laws, including as a hazardous waste, hazardous material, hazardous substance, extremely hazardous waste, restricted
hazardous waste, contaminant, pollutant, toxic waste, or toxic substance, and specifically including petroleum and petroleum products,
asbestos, radon, lead, toxic mold, radioactive materials, and polychlorinated biphenyls.


 






    10


     


    

 


(m) Authorizations;
Regulatory Compliance. The Company and each of its Subsidiaries holds, and is operating in compliance with, all authorizations,
licenses, permits, approvals, clearances, registrations, exemptions, consents, certificates, waivers, filings, qualifications and
orders of each applicable entity or body exercising executive, legislative, judicial, regulatory or administrative functions of
or pertaining to United States federal, state or local government or foreign, or other governmental, including any department,
commission, board, agency, bureau, official or other regulatory, administrative or judicial or arbitral authority thereto (each
a “Governmental Authority”) and supplements and amendments thereto (collectively, “Authorizations”)
required for the conduct of its business as currently conducted and as described in the Super 8-K, or that are otherwise material
to the business of the Company and its Subsidiaries, in all applicable jurisdictions, except as would not reasonably be expected
to be material to the business of the Company and its Subsidiaries, taken as a whole. All Authorizations held by the Company or
its Subsidiaries are valid and in full force and effect. Neither the Company nor any of its Subsidiaries is in material violation
of any terms of any such Authorizations; and neither the Company nor any of its Subsidiaries has received written notice from any
Governmental Authority of any revocation or modification of any such Authorization, or written notice (or to the Company’s
knowledge, oral notice) that such revocation or modification is being considered, except to the extent that any such revocation
or modification would not be reasonably expected to be material to the business of the Company and its Subsidiaries, taken as a
whole. The Company and each of its Subsidiaries is in compliance, and has since the Lookback Date been in compliance, with all
applicable federal, state, local and foreign Laws, including such Laws applicable to the manufacture, distribution, import and
export of regulated products and component parts, except as would not reasonably be expected to be material to the business of
the Company and its Subsidiaries, taken as a whole. The Company and each of its Subsidiaries, and to the Company’s knowledge,
each of their respective directors, officers, employees and agents, is and has been in material compliance with applicable health
care Laws, including, to the extent applicable, without limitation, the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)),
the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), as amended by the Health Information
Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. § 17921 et seq.), and the regulations promulgated pursuant
to such Laws, and comparable state Laws and foreign Laws (collectively, “Health Care Laws”). Neither
the Company nor any of its Subsidiaries has received written notice (or to the Company’s knowledge, oral notice) of any ongoing
claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Authority
or third party alleging that any product operation or activity is in material violation of any Health Care Laws or any Authorizations.
The Company and each of its Subsidiaries has filed, obtained, maintained or submitted all material reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments thereto as required by any Health Care Laws or any Authorizations
and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments, to the
Company’s knowledge, were complete, correct and not misleading on the date filed in all material respects (or were corrected
or supplemented by a subsequent submission). Neither the Company nor any of its Subsidiaries is a party to any corporate integrity
agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, or similar agreements, or has
any reporting obligations pursuant to any such agreement, plan or correction or other remedial measure entered into with any Governmental
Authority. Neither the Company nor any of its Subsidiaries has received any Form FDA 483, warning letter, untitled letter or other
correspondence or written notice from any Governmental Authority, alleging or asserting noncompliance with the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. § 301 et seq.) (“FDCA”) or comparable foreign Laws. Neither the Company nor any of
its Subsidiaries has been notified, either orally or in writing, by any Governmental Authority that a clinical study has been put
on hold or may be put on hold.


 






    11


     


    

 


(n) Title.
Neither the Company nor any of its Subsidiaries owns any real property. Except as set forth on Schedule 3n,
each of the Company and its Subsidiaries has good and marketable title to all of its personal property and other tangible
assets (i) purportedly owned or used by them as reflected in the SEC Reports, as of their respective dates, or (ii) necessary
for the conduct of their business as currently conducted and as described in the Super 8-K, free and clear of any legal or
equitable, specific or floating, lien (statutory or otherwise), restriction, mortgage, deed of trust, pledge, lien, security
interest, restrictive covenant, or other adverse right, charge, claim or encumbrance of any kind or nature whatsoever
(collectively, “Liens”), except for Liens which would not reasonably be expected to have a Material
Adverse Effect. Except as set forth on Schedule 3n, with respect to properties and assets it leases, each of
the Company and its Subsidiaries is in compliance with such leases and holds a valid leasehold interest free of any Liens,
except for such Liens which would not reasonably be expected to have a Material Adverse Effect.


 


(o) Tax
Status. The Company and each Subsidiary has filed (taking into account any valid extensions) all federal and state income and
all other material returns, declarations, reports, elections, designations, or information returns or statements made to a governmental
authority relating to Taxes, including any schedules or attachments thereto and any amendments thereof (collectively, “Tax
Returns”) required to be made or filed by it or with respect to it by any jurisdiction to which it is subject. Such
Tax Returns accurately reflect, in all material respects, the Tax liabilities of the Company and its Subsidiaries (other than Taxes
not yet due and payable). The Company and each Subsidiary has timely paid all income Taxes and all other material Taxes, shown
or determined to be due on such returns, reports and declarations, except those being contested in good faith and for which the
Company and its Subsidiaries have adequately reserved and accrued for in accordance with GAAP. The Company has reserved and accrued
on its books provisions in accordance with GAAP amounts that are reasonably adequate for the payment of all material taxes for
periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid Taxes in any material
amount claimed to be due from the Company or any Subsidiary by the taxing authority of any jurisdiction. There are no, and since
the Lookback Date there have been no, pending or threatened in writing (or to the Company’s knowledge, threatened orally)
Actions by the taxing authority of any jurisdiction against the Company or any of its Subsidiaries. Neither the Company nor any
of its Subsidiaries is a party to, or otherwise bound by, any Tax indemnity, Tax sharing or Tax allocation agreement (but not including
any agreement whose primary subject matter is not Taxes) (a “Tax Agreement”). The Company is not a “United
States real property holding corporation” within the meaning of Section 897(c) of the Code. For purposes of this Agreement,
“Tax” or “Taxes” means (i) any and all U.S. federal, state, local, or non-U.S.
taxes, assessment, levy or other charges, including net or gross income, gross receipts, net proceeds, estimated, sales, use, ad
valorem, value added, franchise, license, withholding, payroll, employment, excise, property (including both real and personal),
unclaimed property remittance/escheat, deed, stamp, alternative or add-on minimum, occupation, severance, unemployment, social
security, workers’ compensation, capital, premium, windfall profit, environmental, custom duties, fees, transfer and registration
taxes, and any governmental charges in the nature of a tax imposed by a Governmental Authority, (ii) any liability for the payment
of any amounts of any of the foregoing types as a result of being a member of an affiliated, consolidated, combined or unitary
group, or being a party to any agreement or arrangement whereby liability for payment of such amounts was determined or taken into
account with reference to the liability of any other person and (iii) any liability for the payment of any amounts as a result
of being a party to any Tax Agreement.


 


(p) Certain
Transactions. Except as set forth on Schedule 3p, none of the direct or indirect equity holders, stockholders,
controlling persons, partners, managers, members, officers, directors, employees, general or limited partners or assignees (each,
a “Related Party”) of the Company or any Subsidiary is presently, or has since the Lookback Date been,
a party to any Contract or transaction with the Company or any Subsidiary (other than for services as employees, officers and directors),
including any Contract providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company,
any corporation, partnership, trust or other entity in which any officer, director, or any such employee has a substantial interest
or is an officer, director, trustee or partner. All transactions that would be required to be disclosed by the Company pursuant
to Item 404 of Regulation S-K promulgated under the Securities Act are disclosed in the SEC Reports (or are disclosed in the Draft
Super 8-K and will be disclosed in the Super 8-K) in accordance with Item 404 of Regulation S-K.


 


(q) Rights
of First Refusal. Except as set forth on Schedule 3q, the Company is not obligated to offer the securities offered
hereunder on a right of first refusal basis or otherwise to any third parties including, but not limited to, current or former
stockholders of the Company, underwriters, brokers, agents or other third parties.


 






    12


     


    

 


(r) Insurance.
The Company and its Subsidiaries have insurance policies of the type and in amounts customarily carried by organizations conducting
businesses or owning assets similar to those of the Company and its Subsidiaries, and in any event maintain insurance policies
in amounts as required by applicable Law or any Contract to which the Company or its Subsidiaries is a party or to which any of
its assets or businesses is subject. All such insurance policies are in full force and effect and binding and enforceable in accordance
with their terms, and all premiums due and payable thereon have been timely paid in full. Neither the Company nor any of its Subsidiaries
is in default with respect to its obligations under any such insurance policy, nor has there been any failure to give any notice
or present any claim under any such insurance policy in due and timely fashion except as would not, individually or in the aggregate,
reasonably be expected to be material to the business of the Company and its Subsidiaries, taken as a whole. There is no material
claim pending under any such policy as to which coverage has been questioned, denied or disputed by the underwriter of such policy
and there has been no notice of cancellation of nonrenewal of any such insurance policy received by the Company or any of its Subsidiaries.
Since the Lookback Date, no limits on any insurance policy of the Company or any of its Subsidiaries have been exhausted, materially
eroded or materially reduced.


 


(s) SEC
Reports. The Company has timely filed or furnished , as applicable, all reports, proxy statements, schedules, forms, statements,
certifications and other documents (including exhibits and all other information incorporated by reference therein) required to
be filed or furnished by the Company under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder (the “Exchange Act”) (together with the Super 8-K, the “SEC Reports”)
since the Lookback Date (or such shorter period since the Company was first required by Law or regulation to file such material).
The Draft Super 8-K will not materially deviate from the Super 8-K as filed with the SEC. The Draft Super 8-K complies, the Super
8-K when filed will comply, and the other SEC Reports at the time they were filed complied, in all material respects with the Securities
Act or the Exchange Act, as applicable. There are no Contracts that are required to be described in the SEC Reports and/or to be
filed as exhibits thereto that were not described, in all material respects, and/or filed as required. There has not been any material
change or amendment to, or any waiver of any material right under, any such Contract that has not been described in and/or filed
as an exhibit to the SEC Reports. There are no outstanding or unresolved comments in comment letters received from the SEC staff
with respect to the SEC Reports. None of the SEC Reports is the subject of an ongoing SEC review. There are no SEC inquiries or
investigations, other governmental inquiries or investigations or internal investigations pending or threatened in writing (or,
to the Company’s knowledge, threatened orally), in each case regarding any accounting practice of the Company.


 






    13


     


    

 


(t)
Financial Statements.


 


(i) (A)
The audited consolidated financial statements of Augmedix for the fiscal year ended December 31, 2019, the unaudited interim consolidated
financial statements of Augmedix for the quarter ended June 30, 2020 and the unaudited pro forma consolidated financial statements
of the Company (after taking into effect the Merger) (including, in each case, the notes thereto) to be included in the Super 8-K
will, at the time of such filing of the Super 8-K, comply in all material respects with GAAP and the rules and regulations of the
SEC with respect thereto as in effect at the time of filing and (B) true and complete copies of the consolidated audited financial
statements of Augmedix and its Subsidiaries consisting of the balance sheets of the Company and its Subsidiaries as at December
31, 2018 and December 31, 2019 and the related statements of income and retained earnings, owners’ equity and cash flow for
the years then ended including, in each case, the notes thereto, have been made available to the Purchaser (the financial statements
referenced in the foregoing clauses (i) and (ii), the “Financial Statements”). The Financial Statements
have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) applied
on a consistent basis during the periods involved and include all adjustments (consisting only of normal recurring accruals) that
are necessary for a fair presentation of the consolidated financial condition of the entities or business to which they relate
as of the date thereof, subject, in the case of the unaudited interim consolidated financial statements of Augmedix for the quarter
ended June 30, 2020, to normal year-end adjustments that will not, individually or in the aggregate, be material and the absence
of notes, and fairly present in all material respects the financial position of Augmedix and its Subsidiaries taken as a whole,
or the Company and its consolidated Subsidiaries taken as a whole, as applicable, as of and for the dates thereof and the results
of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, year-end audit
adjustments that will not, individually or in the aggregate, be material. The pro forma financial information and the related notes,
if any, included in the SEC Reports have been properly compiled and prepared in accordance with the applicable requirements of
the Securities Act and fairly present in all material respects the information shown therein, and the assumptions used in the preparation
thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred
to therein.


 


(ii) The
Company (A) maintains a standard system of accounting established and administered in accordance with GAAP and (B) has established
and maintains a system of internal controls over financial reporting designed to provide reasonable assurance regarding the reliability
of the financial reporting and the preparation of the Financial Statements for external purposes in accordance with GAAP. There
(x) are no significant deficiencies or weaknesses in any system of internal accounting controls used by each of the Company’s
Subsidiaries, (y) has not since the Lookback Date been any fraud or other unlawful act on the part of any of management or other
employees of the Company and each of its Subsidiaries who have a role in the preparation of Financial Statements or the internal
accounting controls used by the Company and each of its Subsidiaries related to such preparation or controls and (z) has not since
the Lookback Date been any claim or allegation regarding any of the foregoing.


 


(iii) Neither
the Company nor any of its Subsidiaries has any liabilities (whether accrued, absolute, contingent or otherwise) other than (A)
liabilities disclosed on the audited balance sheet (including the notes thereto) or the interim balance sheet (including the notes
thereto) and (B) liabilities that have been incurred since the date of the latest balance sheet of the Company and the latest balance
sheet of Augmedix included in the Financial Statements in the ordinary course of business, which liabilities, individually or in
the aggregate, are not material to the business of the Company and its Subsidiaries (taken as a whole).


 






    14


     


    

 


(u) Material Changes.
Except for the transactions contemplated hereby or in the Merger Agreement, since the date of the latest balance sheet of the Company
and the latest balance sheet of Augmedix included in the financial statements contained within the SEC Reports, except as set forth
on Schedule 3(u), (i) there have been no events, occurrences or developments that have had or would reasonably be
expected to have a Material Adverse Effect with respect to the Company or Augmedix, (ii) there have not been any changes in the
assets, financial condition, business or operations of the Company or Augmedix from that reflected in the financial statements
contained within the SEC Reports except changes in the ordinary course of business which have not been, either individually or
in the aggregate, materially adverse to the business, properties, financial condition, results of operations or future prospects
of the Company or Augmedix, (iii) none of the Company or Augmedix or any of their respective Subsidiaries has altered its method
of accounting or the manner in which it keeps its accounting books and records, and (iv) none of the Company or Augmedix or any
of their respective Subsidiaries has declared or made any dividend or distribution of cash or other property to its stockholders
or equity holders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock (other than
in connection with repurchases of unvested stock issued to employees of the Company). The Company and its Subsidiaries, individually
and on a consolidated basis, are not as of the date hereof, and after giving effect to the transactions contemplated hereby to
occur at the Initial Closing, will not be Insolvent (as defined below). “Insolvent” means, with respect
to the Company, on a consolidated basis with its Subsidiaries, (i) the present fair saleable value of the Company’s and its
Subsidiaries’ assets is less than the amount required to pay the Company’s and its Subsidiaries’ total indebtedness,
(ii) the Company and its Subsidiaries are unable to pay their debts and liabilities, subordinated, contingent or otherwise, as
such debts and liabilities become absolute and matured or (iii) the Company and its Subsidiaries intend to incur or believe that
they will incur debts that would be beyond their ability to pay as such debts mature.


 


(v) Disclosure
Controls. The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-14 and 15d-15
under the Exchange Act) and such controls and procedures are effective in ensuring that material information relating to the Company,
including its Subsidiaries, is made known to the principal executive officer and the principal financial officer.


 


(w) Sarbanes-Oxley.
The Company is, and has been since the Lookback Date, to the extent applicable, in compliance in all material respects with all
of the provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it.


 


(x) Off-Balance
Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company or any Subsidiary and an
unconsolidated or other off-balance sheet entity that is required to be disclosed by the Company in its SEC Reports (including,
for purposes hereof, any that are required to be disclosed in a Form 10) and is not so disclosed.


 


(y) Foreign
Corrupt Practices. Neither the Company and its Subsidiaries, nor any of their respective directors, managers, officers, agents
or employees or other person acting on behalf of the Company or its Subsidiaries, has: (i) directly or indirectly, used any funds
for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii) made any unlawful payment or offered anything of value to foreign or domestic government officials or employees or to any
foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by
the Company or any of its Subsidiaries (or, to the Company’s knowledge, made by any person acting on their behalf) which
is in violation of Law or (iv) violated any applicable anti-terrorism Law or regulation, nor have any of them otherwise taken any
action which would reasonably cause the Company or any of its Subsidiaries to be in violation of the Foreign Corrupt Practices
Act of 1977, as amended, or any applicable Law of similar effect.


 




    15


     


    

 


(z) Office
of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director, manager,
officer, agent, employee or Affiliate of the Company or any Subsidiary is, or is acting under the direction of, on behalf of or
for the benefit of a person that is, or is owned or controlled by a person that is, currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Treasury Department.


 


(aa) Money Laundering.
The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial
record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering Laws and applicable rules and regulations thereunder (collectively, the “Money Laundering Laws”),
and no Action by or before any Governmental Authority involving the Company or any Subsidiary with respect to the Money Laundering
Laws is pending or threatened in writing (or to the Company’s knowledge, threatened orally).


 


(bb) Regulation
M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of,
any of the Securities, or (iii) paid or agreed to pay to any person any compensation for soliciting another to purchase any other
securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company’s placement
agent in connection with the placement of the Securities.


 


(cc)
Privacy and Data Security.


 


(i) “Business
Privacy and Data Security Policies” means all of the Company’s or one of its Subsidiaries’ present,
internal or public-facing policies, notices, and statements concerning the privacy, security, or Processing of Personal
Information in the conduct of the Business. “Personal Information” means any information that
identifies or, alone or in combination with any other information, could reasonably be used to identify, locate, or contact a
natural person, including name, street address, telephone number, email address, identification number issued by a
Governmental Authority, credit card number, bank information, customer or account number, online identifier, device
identifier, IP address, browsing history, search history, or other website, application, or online activity or usage data,
location data, biometric data, medical or health information, or any other information that is considered “personally
identifiable information,” “personal information,” or “personal data” under applicable Law, and
all data associated with any of the foregoing that are or could reasonably be used to develop a profile or record of the
activities of a natural person across multiple websites or online services, to predict or infer the preferences, interests,
or other characteristics of a natural person, or to target advertisements or other content to a natural person.
“Privacy Laws” means all applicable Laws, orders, writs, judgments, injunctions, decrees,
stipulations, determinations or awards entered by or with any Governmental Authority, and binding guidance issued by any
Governmental Authority concerning the privacy, security, or Processing of Personal Information (including Laws of
jurisdictions where Personal Information was collected), including, as applicable, data breach notification Laws, consumer
protection Laws, Laws concerning requirements for website and mobile application privacy policies and practices, Social
Security number protection Laws, data security Laws, and Laws concerning email, text message, or telephone communications.
Without limiting the foregoing, Privacy Laws include the Health Insurance Portability and Accountability Act of 1996, as
amended and supplemented by the Health Information Technology for Economic and Clinical Health Act of the American Recovery
and Reinvestment Act of 2009 and all other similar international, federal, state, provincial, and local Laws.
“Processing” means any operation performed on Personal Information, including the collection,
creation, receipt, access, use, handling, compilation, analysis, monitoring, maintenance, storage, transmission, transfer,
protection, disclosure, destruction, or disposal of Personal Information.


 






    16


     


    

 


(ii) The
Company and each of its Subsidiaries, and, to the Company’s knowledge, all vendors, processors, or other third parties acting
for or on behalf of the Company or any of its Subsidiaries in connection with the Processing of Personal Information or that otherwise
have been authorized to have access to Personal Information in the possession or control of the Company or any of its Subsidiaries,
comply and at all times since the Lookback Date have complied, with all of the following in the conduct of its business as currently
conducted and as disclosed in the Super 8-K: (A) Privacy Laws; (B) rules of self-regulatory organizations; (C) industry standards,
guidelines, and best practices; (D) the Business Privacy and Data Security Policies; and (E) all obligations or restrictions concerning
the privacy, security, or Processing of Personal Information under any Contract to which the Company or any of its Subsidiaries
is a party or otherwise bound as of the date hereof, in each case, except for violations that, individually or in the aggregate,
have not been and would not reasonably be expected to be material to the business of the Company and its Subsidiaries, taken as
a whole.


 


(iii) Neither
the consummation of the Merger nor the execution, delivery and performance of this Agreement and the consummation of the transactions
contemplated hereby, does or will: (A) conflict with or result in a violation or breach of any Privacy Laws or Business Privacy
and Data Security Policies (as currently existing or as existing at any time during which any Personal Information was collected
or Processed by or for the Company or any of its Subsidiaries in the conduct of its business as now being conducted); or (B) require
the consent of or notice to any person concerning such person’s Personal Information, in each case, except as has not been
and would not reasonably be expected to have a Material Adverse Effect.


 


(iv) Since
the Lookback Date, (A) no Personal Information in the possession or control of the Company or any of its Subsidiaries, or to the
Company’s knowledge, held or Processed by any vendor, processor, or other third party for or on behalf of the Company or
any of its Subsidiaries, in the conduct of its business has been subject to any data or security breach or unauthorized access,
disclosure, use, loss, denial or loss of use, alteration, destruction, compromise, or Processing (a “Security Incident”),
and (B) neither the Company nor any of its Subsidiaries has notified and, to the Company’s knowledge, there have been no
facts or circumstances that would require the Company or any of its Subsidiaries to notify, any Governmental Authority or other
person of any Security Incident in the conduct of its business, in each case, except as has not been and would not reasonably be
expected to have a Material Adverse Effect.


 


(v) Since
the Lookback Date, neither the Company nor any of its Subsidiaries has received any notice, request, claim, complaint, correspondence,
or other communication in writing (or to the Company’s knowledge, orally) from any Governmental Authority or other person,
and to the Company’s knowledge there has not been any audit, investigation, enforcement action (including any fines or other
sanctions), or other Action relating to, any actual, alleged, or suspected Security Incident or violation of any Privacy Law involving
Personal Information in the possession or control of the Company or any of its Subsidiaries, or held or Processed by any vendor,
processor, or other third party for or on behalf of the Company or any of its Subsidiaries, in the conduct of its business, in
each case, except as has not been and would not reasonably be expected to be material to the business of the Company and its Subsidiaries,
taken as a whole.


 






    17


     


    

 


(vi) In
the conduct of its business, the Company and each of its Subsidiaries has at all times since the Lookback Date implemented and
maintained, and required all vendors, processors, and other third parties that Process any Personal Information for or on behalf
of the Company or any of its Subsidiaries to implement and maintain, all security measures, plans, procedures, controls, and programs,
including written information security programs, to (A) identify and address internal and external risks to the privacy and security
of Personal Information in their possession or control; (B) implement, monitor, and improve adequate and effective administrative,
technical, and physical safeguards to protect such Personal Information and the operation, integrity, and security of its software,
systems, applications, and websites involved in the Processing of Personal Information; and (C) provide notification in compliance
with applicable Privacy Laws in the case of any Security Incident, in each case, except as has not been and would not reasonably
be expected to be material to the business of the Company and its Subsidiaries, taken as a whole.


 


(dd) Brokers’
Fees. Neither of the Company nor any of its Subsidiaries has any liability or obligation to pay any fees or commissions to
any broker, finder or agent with respect to the transactions contemplated by this Agreement, except for the payment of fees to
the Placement Agents as described in Section 2 above.


 


(ee) Disclosure
Materials. The SEC Reports and the Disclosure Materials, at the time filed or furnished, were (or in the case of the Super
8-K, will be) true and correct in all material respects and did not or will not contain an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading. For the purposes of this Agreement, “Disclosure Materials”
means the Confidential and Non-Binding Summary Term Sheet of the Company previously provided to the Purchaser, and any roadshow
presentation delivered to the Purchaser in connection with the contemplated purchase of the Shares, each as amended from time to
time, relating to the Offering and any supplement or amendment thereto, and any disclosure schedule or other information document,
including the Disclosure Schedule, delivered to the Purchaser prior to its execution of this Agreement, and any such document delivered
to the Purchaser after its execution of this Agreement and prior to the closing of the Purchaser’s subscription hereunder,
including the Draft Super 8-K.


 


(ff) Investment
Company. The Company is not required to be registered as, and is not an Affiliate of, and immediately following the Closing
will not be required to register as, an “investment company” within the meaning of the Investment Company Act of 1940,
as amended.


 







    18


     


    

 


(gg) Reliance.
The Company acknowledges that the Purchaser is relying on the representations and warranties (as modified by the disclosures on
the Disclosure Schedule or the Draft Super 8-K (excluding any disclosures (whether contained under the heading “Risk Factors,”
in any “forward-looking statements” disclaimer or in any other section) to the extent they are cautionary, predictive
or forward-looking in nature) made by the Company hereunder and that such representations and warranties (as modified by the Disclosure
Schedule or the Draft Super 8-K (excluding any disclosures (whether contained under the heading “Risk Factors,” in
any “forward-looking statements” disclaimer or in any other section) to the extent they are cautionary, predictive
or forward-looking in nature) are a material inducement to the Purchaser purchasing the Shares. The Company further acknowledges
that without such representations and warranties of the Company made hereunder, the Purchaser would not enter into this Agreement
with the Company.


 


(hh) Bad Actor
Disqualification. No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act
(a “Disqualification Event”) is applicable to the Company or, to the Company’s knowledge, any Company
Covered Person, except for a Disqualification Event as to which Rule 506(d)(2)(ii–iv) or (d)(3), is applicable. “Company
Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated
under the Securities Act, any person listed in the first paragraph of Rule 506(d)(1). The Company represents that it has exercised
reasonable care to determine the accuracy of the representation made by the Company in this paragraph.


 


(ii) Anti-Dilution.
There are no securities or instruments issued by or to which the Company is a party as of the date hereof or as of the Closing
containing anti-dilution or similar provisions that will be triggered by the issuance of shares of Common Stock in connection with
the Offering or pursuant to any other Subscription Agreement entered into in connection with the Offering that have not been or
will not be validly waived on or prior to each Closing Date.


 


(jj) Other Purchasers.
The Company has not entered into any side letter or similar agreement with any Other Purchaser in connection with such Other Purchaser’s
direct or indirect investment in the Company other than the applicable Other Subscription Agreement. Each Other Purchaser will
enter into the applicable Other Subscription Agreement and no other side letters or similar agreements with respect to its investment
in the shares of Common Stock in connection with the Offering. Each Other Subscription Agreement is in the same form and contains
the same terms and provisions as this Agreement.


 


(kk) Leased Real
Property. There are no pending or, to the knowledge of the Company, any threatened condemnation proceedings, lawsuits or other
Actions relating to any real property leased by the Company or any of its Subsidiaries or any of the buildings, structures and
facilities located thereon (the “Leased Real Property”) or other matters affecting adversely the current
use, occupancy or value thereof. The Company and its applicable Subsidiaries enjoy quiet possession under all leases for each parcel
of Leased Real Property (each, a “Lease”) and no Leased Real Property under any such Lease is subject
to any Lien, easement, right-of-way, building or use restriction, exception, variance, reservation or limitation, as might, in
any material respect, interfere with or impair the present and continued use thereof by the Company or its Subsidiaries in the
usual and normal conduct of the business of the Company and its Subsidiaries.


 






    19


     


    

 


(ll)
Material Contracts.


 


(i) “Material
Contracts” means any written or oral agreement, contract, commitment, arrangement, subcontract, license,
sublicense, lease, sublease, sales order, purchase order, indenture, mortgage, note, bond, letter of credit, warrant,
instrument, obligation, or understanding (collectively, including all amendments, supplements and modifications thereto,
“Contracts”) to which the Company or any of its Subsidiaries is a party or by which any of their
respective assets or businesses are bound that is a “material contract” (as such term is defined in Item
601(b)(10) of Regulation S-K promulgated under the Securities Act) and is included as an exhibit to the Super 8-K.


 


(ii) Each
Material Contract is the legal, valid and binding obligation of the Company or one of its Subsidiaries that is a party thereto,
and is enforceable against the Company or one of its Subsidiaries, as applicable, and, to the knowledge of the Company, the counterparties,
in accordance with its terms, other than, in all cases, Material Contracts that have expired, been terminated or superseded in
accordance with their terms following the date hereof. Neither the Company or any of its Subsidiaries, nor to the knowledge of
the Company, any counterparty, is in violation, breach or default under any such Contract or has improperly terminated, revoked
or accelerated any Material Contract and no event or condition exists or has occurred which, with the giving of notice or the lapse
of time or both, would, under any Material Contract, (A) constitute a breach or default by the Company or any of its Subsidiaries,
or to the knowledge of the Company, a counterparty, (B) give to the counterparty any rights of termination, acceleration or cancellation
of, (C) result in any obligation imposed on the Company or any of its Subsidiaries thereunder or a loss of a benefit in favor of
the Company or any of its Subsidiaries thereunder, (D) allow the imposition of any fees or penalties on the Company or any of its
Subsidiaries thereunder, require the offering or making of any payment or redemption by the Company or any of its Subsidiaries
thereunder or (E) give rise to any increased, guaranteed, accelerated or additional rights or entitlements to the counterparty
thereunder, in each case, except for (i) such breaches, defaults and events which would not reasonably be expected to have a Material
Adverse Effect, and (ii) any Material Contracts that will expire or terminate in accordance with their terms in connection with
or as contemplated by or directly related to the Merger Agreement and the transactions contemplated thereby, including to the extent
applicable, Contracts with the stockholders or investors of the Company or any of its Subsidiaries, indemnification agreements
with each of their respective directors or officers, employment, consulting agreements or equity award agreements with each of
their employees or other service providers. None of the Company or any of its Subsidiaries has received any written notice of the
intention of any person to terminate, fail to renew or materially and adversely modify any Material Contract.


 


(mm)
Employee Benefits.


 


(i) “Benefit
Plan” means any plan, program, arrangement or agreement that is a pension, profit-sharing, savings, retirement, employment,
consulting, severance pay, termination, executive compensation, incentive compensation, deferred compensation, bonus, stock purchase,
stock option, phantom stock or other equity-based compensation, change-in-control, retention, salary continuation, vacation, sick
leave, disability, death benefit, group insurance, hospitalization, medical, dental, life (including all individual life insurance
policies as to which the Company is the owner, the beneficiary, or both), Code Section 125 “cafeteria” or “flexible”
benefit, employee loan, educational assistance or fringe benefit plan, program, arrangement or agreement, whether written or oral,
including, without limitation, any (A) “employee benefit plan” within the meaning of Section 3(3) of the Employee Retirement
Income Security Act of 1974, as amended, and the rules and regulations promulgated thereunder (“ERISA”)
or (B) other employee benefit plans, agreements, programs, policies, arrangements or payroll practices, whether or not subject
to ERISA (including any funding mechanism therefor now in effect or required in the future as a result of the transaction contemplated
by this Agreement or otherwise), which the Company or any of its Subsidiaries sponsors or maintains for the benefit of its current
or former officer, director, employee, leased employee, consultant or agent (or their respective beneficiaries), or with respect
to which the Company or any of its Subsidiaries has, or could reasonably be expected to have, any direct or indirect present or
future liability.


 






    20


     


    

 


(ii) Each
Benefit Plan has been established, maintained and operated in all respects in accordance with its terms and in compliance with
all applicable provisions of applicable Laws, including Section 409A of the Code and the regulations and other guidance issued
thereunder, in each case, except as has not been and would not reasonably be expected to have, a Material Adverse Effect. There
are no investigations by any Governmental Authority, termination proceedings or other claims (except routine claims for benefits
payable under the Benefit Plans) or Actions pending in writing (or to the Company’s knowledge, orally) against any Benefit
Plan or asserting any rights to or claims for benefits under any Benefit Plan that would reasonably be expected to give rise to
any material liability. No non-exempt “prohibited transaction” (within the meaning of Section 406 of ERISA and Section
4975 of the Code) has occurred or is reasonably expected to occur with respect to any Benefit Plan. No Benefit Plan is (A) subject
to Section 412 of the Code, Title IV of ERISA or Section 302 of ERISA (including a “multiemployer” plan within the
meaning of Section 3(37) of ERISA), (B) a “multiple employer plan” as defined in Section 413(c) of the Code, or (C)
a “multiple employer welfare arrangement” within the meaning of Section 3(40) of ERISA. No Benefit Plan is subject
to the Laws of any jurisdiction other than the United States.


 


4. Representations,
Warranties and Agreements of the Purchaser. The Purchaser represents and warrants to, and agrees with, the Company, as
of the date hereof and as of the applicable Closing Date, the following:


 


(a) The
Purchaser has the knowledge and experience in financial and business matters necessary to evaluate the merits and risks of its
prospective investment in the Company, and has carefully reviewed and understands the risks of, and other considerations relating
to, the purchase of Shares and the tax consequences of the investment. The Purchaser has adequate means of providing for its current
and anticipated financial needs and contingencies, and is able to bear the economic risks of the investment for an indefinite period
of time and has no need for liquidity of the investment in the Shares. The Purchaser can afford the loss of his, her or its entire
investment.


 


(b) The
Purchaser is acquiring the Shares for investment for his, her or its own account and not with the view to, or for resale in connection
with, any distribution thereof. The Purchaser understands and acknowledges that the Offering and sale of the Shares have not been
registered under the Securities Act or any state securities Laws, by reason of a specific exemption from the registration provisions
of the Securities Act and applicable state securities Laws, which depends upon, among other things, the bona fide nature of the
investment intent as expressed herein. The Purchaser further represents that he, she or it does not have any contract, undertaking,
agreement or arrangement with any person to sell, transfer or grant participation to any third person with respect to any of the
Shares, other than with respect to an Affiliate of the Purchaser. The Purchaser understands and acknowledges that the Offering
of the Shares will not be registered under the Securities Act nor under the state securities laws on the ground that the sale of
the Shares to the Purchaser as provided for in this Agreement and the issuance of securities hereunder is exempt from the registration
requirements of the Securities Act and any applicable state securities laws. The Purchaser is an “accredited investor”
as defined in Rule 501 of Regulation D as promulgated by the SEC under the Securities Act for the reason(s) specified on the Accredited
Investor Certification attached hereto as completed by the Purchaser. The Purchaser resides in the jurisdiction set forth on the
Purchaser’s Omnibus Signature Page affixed hereto. If the Purchaser is, with respect to the Company, (i) a predecessor of
the Company; (ii) an affiliated issuer; (iii) a director, executive officer, other officer participating in the offering, general
partner or managing member of the Company; (iii) any beneficial owner of 20% or more of the Company's outstanding voting equity
securities, calculated on the basis of voting power; (iv) any promoter connected with the Company in any capacity at the time of
such sale; (v) any investment manager of the Company if the Company is a pooled investment fund; (vi) any person that has been
or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the Offering; (vii) any
general partner or managing member of any such investment manager or solicitor; or (viii) any director, executive officer or other
officer participating in the offering of any such investment manager or solicitor or general partner or managing member of such
investment manager or solicitor (each such category, a “Covered Person”), the Purchaser has not taken
any of the actions set forth in, and is not subject to, the disqualification provisions of Rule 506(d)(1) of the Securities Act.


 






    21


     


    

 


(c) The
Purchaser (i) if a natural person, represents that he or she is the greater of (A) 21 years of age or (B) the age of legal majority
in his or her jurisdiction of residence, and has full power and authority to execute and deliver this Agreement and all other related
agreements or certificates and to carry out the provisions hereof and thereof; (ii) if a corporation, partnership, limited liability
company, association, joint stock company, trust, unincorporated organization or other entity, represents that such entity is duly
organized, validly existing and in good standing under the Laws of the state or jurisdiction of its organization, the consummation
of the transactions contemplated hereby is authorized by, and will not result in a violation of applicable Law or its charter or
other organizational documents, such entity has full power and authority to execute and deliver this Agreement and all other related
agreements or certificates and to carry out the provisions hereof and thereof and to purchase and hold the Shares, the execution
and delivery of this Agreement has been duly authorized by all necessary action, this Agreement has been duly executed and delivered
on behalf of such entity and is a legal, valid and binding obligation of such entity; or (iii) if executing this Agreement in a
representative or fiduciary capacity, represents that he, she or it has full power and authority to execute and deliver this Agreement
in such capacity and on behalf of the subscribing individual, ward, partnership, trust, estate, corporation, or limited liability
company or partnership, or other entity for whom the Purchaser is executing this Agreement, and such individual, partnership, ward,
trust, estate, corporation, or limited liability company or partnership, or other entity has full right and power to perform pursuant
to this Agreement and make an investment in the Company, and represents that this Agreement constitutes a legal, valid and binding
obligation of such entity. The execution and delivery of this Agreement will not violate or be in conflict with any order, judgment,
injunction, agreement or controlling document to which the Purchaser is a party or by which it is bound, except for any violation
or conflict that, individually or in the aggregate, has not had and would not reasonably be expected to have a material adverse
effect on the ability of the Purchaser to perform its obligations under this Agreement and the other Transaction Documents or to
consummate any transactions contemplated hereby or thereby.


 


(d) The
Purchaser understands that the Shares are being offered and sold to him, her or it in reliance on specific exemptions from the
registration requirements of United States federal and state securities Laws and that the Company is relying in part upon the truth
and accuracy of, and the Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and understandings
of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser
to acquire such securities. The Purchaser further acknowledges and understands that the Company is relying on the representations
and warranties made by the Purchaser hereunder and that such representations and warranties are a material inducement to the Company
to sell the Shares to the Purchaser. The Purchaser further acknowledges that without such representations and warranties of the
Purchaser made hereunder, the Company would not enter into this Agreement with the Purchaser.


 


(e) The
Purchaser understands that, other than as expressly provided in the Registration Rights Agreement, the Company does not currently
intend to register the Shares under the Securities Act at any time in the future; and the undersigned will not immediately be entitled
to the benefits of Rule 144 with respect to the Shares. The Purchaser understands that no public market exists for the Company’s
Common Stock and that there can be no assurance that any public market for the Common Stock will exist or continue to exist. The
Company’s Common Stock is not approved for quotation on OTC Markets or any other quotation system or listed on any exchange.


 


(f) The
Purchaser has received, reviewed and understood the information about the Company, including all Disclosure Materials provided
to it by the Company and/or the Placement Agents (at the Company’s direction), and has had an opportunity to discuss the
Company’s business, management and financial affairs with the Company’s management. The Purchaser understands that
such discussions, as well as any Disclosure Materials provided by the Company and/or the Placement Agents (at the Company’s
direction), were intended to describe the aspects of the Company’s business and prospects and the Offering which the Company
believes to be material, but were not necessarily a thorough or exhaustive description and except as expressly set forth in this
Agreement (as modified by the disclosures on the Disclosure Schedule or the Draft Super 8-K (excluding any disclosures contained
under the heading “Risk Factors,” any disclosures of risks included in any “forward looking statements”
or disclosures that are cautionary, predictive or forward-looking in nature)), the Company makes no representation or warranty
with respect to the completeness of such information and makes no representation or warranty of any kind with respect to any information
provided by any entity other than the Company. Some of such information may include projections as to the future performance of
the Company, which projections may not be realized, may be based on assumptions which may not be correct and may be subject to
numerous factors beyond the Company’s control. The Purchaser acknowledges that he, she or it is not relying upon any person
or entity, other than the Company and its officers and directors, in making its investment or decision to invest in the Company.


 


(g) The
Purchaser acknowledges that none of the Company or the Placement Agents is acting as a financial advisor or fiduciary of the Purchaser
(or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby, and
no investment advice has been given by the Company, the Placement Agents or any of their respective representatives or agents in
connection with the Transaction Documents and the transactions contemplated hereby and thereby.


 






    22


     


    

 


(h) As
of the applicable Closing, all actions on the part of the Purchaser, and its officers, directors and partners, if applicable, necessary
for the authorization, execution and delivery of this Agreement and the Registration Rights Agreement and the performance of all
obligations of the Purchaser hereunder and thereunder shall have been taken, and this Agreement and the Registration Rights Agreement,
assuming due execution by the parties hereto and thereto, constitute valid and legally binding obligations of the Purchaser, enforceable
in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar Laws relating to, or affecting generally, the enforcement
of creditors’ rights and remedies.


 


(i) The
Purchaser represents that neither it nor, to its knowledge, any person or entity controlling, controlled by or under common control
with it, nor any person having a beneficial interest in the Purchaser, nor any person on whose behalf the Purchaser is acting:
(i) is a person listed in the Annex to Executive Order No. 13224 (2001) issued by the President of the United States (Executive
Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism); (ii) is
named on the List of Specially Designated Nationals and Blocked Persons maintained by the U.S. Office of Foreign Assets Control;
(iii) is a non-U.S. shell bank or is providing banking services indirectly to a non-U.S. shell bank; (iv) is a senior non-U.S.
political figure or an immediate family member or close associate of such figure; or (v) is otherwise prohibited from investing
in the Company pursuant to applicable U.S. anti-money laundering, anti-terrorist and asset control Laws, regulations, rules or
orders (categories (i) through (v), each a “Prohibited Purchaser”). The Purchaser (A) agrees to provide
the Company, promptly upon request, all information that the Company reasonably deems necessary or appropriate to comply with applicable
U.S. anti-money laundering, anti-terrorist and asset control Laws, regulations, rules and orders and (B) consents to the disclosure
to U.S. regulators and law enforcement authorities by the Company and its Affiliates and agents of such information about the Purchaser
as the Company reasonably deems necessary or appropriate to comply with applicable U.S. anti-money laundering, anti-terrorist and
asset control Laws, regulations, rules and orders. If the Purchaser is a financial institution that is subject to the USA Patriot
Act, the Purchaser represents that it has met all of its obligations under the USA Patriot Act. The Purchaser acknowledges that
if, following its investment in the Company, the Company reasonably believes that the Purchaser is a Prohibited Purchaser or is
otherwise engaged in suspicious activity or refuses to promptly provide information that the Company requests, the Company has
the right or may be obligated to prohibit additional investments, segregate the assets constituting the investment in accordance
with applicable regulations or immediately require the Purchaser to transfer the Shares. The Purchaser further acknowledges that
neither the Purchaser nor any of the Purchaser’s Affiliates or agents will have any claim against the Company or Augmedix
for any form of damages as a result of any of the foregoing actions.


 


(j) If
the Purchaser is an Affiliate of a non-U.S. banking institution (a “Foreign Bank”), or if the Purchaser
receives deposits from, makes payments on behalf of, or handles other financial transactions related to a Foreign Bank, the Purchaser
represents and warrants to the Company that: (1) the Foreign Bank has a fixed address, other than solely an electronic address,
in a country in which the Foreign Bank is authorized to conduct banking activities; (2) the Foreign Bank maintains operating records
related to its banking activities; (3) the Foreign Bank is subject to inspection by the banking authority that licensed the Foreign
Bank to conduct banking activities; and (4) the Foreign Bank does not provide banking services to any other Foreign Bank that does
not have a physical presence in any country and that is not a regulated Affiliate.


 






    23


     


    

 


(k) The
Purchaser or its duly authorized representative realizes that because of the inherently speculative nature of businesses of the
kind conducted and contemplated by the Company, the Company’s financial results may be expected to fluctuate from month to
month and from period to period and will, generally, involve a high degree of financial and market risk that could result in substantial
or, at times, even total losses for investors in securities of the Company. The Purchaser has considered the risk factors in the
Draft Super 8-K before deciding to invest in the Shares.


 


(l) The
Purchaser is not subscribing for Shares as a result of or subsequent to any advertisement, article, notice or other communication,
published in any newspaper, magazine or similar media or broadcast over television, radio, or the internet, or presented at any
seminar or meeting, or any solicitation of a subscription by a person not previously known to the Purchaser in connection with
investments in securities generally.


 


(m) The
Purchaser acknowledges that no U.S. federal or state agency or any other government or governmental agency has passed upon the
Shares or made any finding or determination as to the fairness, suitability or wisdom of any investments therein.


 


(n) Other
than consummating the transactions contemplated hereunder, the Purchaser has not directly or indirectly, nor has any individual
or entity acting on behalf of or pursuant to any understanding with the Purchaser, executed any purchases or sales, including Short
Sales (as defined below), of the securities of the Company during the period commencing at the time the Purchaser was first contacted
by the Company or any other individual or entity representing the Company (including one or more of the Placement Agents) regarding
the transactions contemplated hereunder. Notwithstanding the foregoing, in the case of the Purchaser being a multi-managed investment
vehicle whereby separate portfolio managers manage separate portions of the Purchaser’s assets and the portfolio managers
do not communicate or share information with, and have no direct knowledge of the investment decisions made by, the portfolio managers
managing other portions of the Purchaser’s assets, the representation set forth above shall only apply with respect to the
portion of assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Agreement.
Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty,
or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow
in order to effect Short Sales or similar transactions in the future. For purposes of this Agreement, “Short Sales”
means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to
include the location and/or reservation of borrowable shares of Common Stock).


 


(o) The
Purchaser is aware that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of the Shares and
other activities with respect to the Shares by the Purchaser, and will comply with such anti-manipulation rules of Regulation M.


 







    24


     


    

 


(p) All
of the information concerning the Purchaser set forth herein, and any other information furnished by the Purchaser in writing to
the Company or a Placement Agent for use in connection with the transactions contemplated by this Agreement, is true, correct and
complete in all material respects as of the date of this Agreement, and, if there should be any material change in such information
prior to the Purchaser’s purchase of the Shares, the Purchaser will promptly furnish revised or corrected information to
the Company.


 


(q) The
Purchaser has reviewed with its own tax advisors the U.S. federal, state, local and foreign tax consequences of this investment
and the transactions contemplated by the Transaction Documents. With respect to such matters, the Purchaser relies solely on such
advisors and not on any statements or representations of the Company or any of its agents, written or oral. The Purchaser understands
that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the
transactions contemplated by the Transaction Documents.


 


(r) If
the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code of 1986, as amended),
the Purchaser hereby represents that it has satisfied itself as to the observance in all material respects of the Laws of its jurisdiction
in connection with any invitation to subscribe for the Shares or any use of this Agreement, including (a) the legal requirements
within its jurisdiction for the purchase of the Shares; (b) any foreign exchange restrictions applicable to such purchase; (c)
any governmental or other consents that may need to be obtained; and (d) the income tax and other tax consequences, if any, that
may be relevant to the purchase, holding, redemption, sale or transfer of the Shares. The Purchaser’s subscription and payment
for and continued beneficial ownership of the Shares will not violate any applicable securities or other Laws of the Purchaser’s
jurisdiction.


 


(s) The
Purchaser represents that it is not a “foreign person” for purposes of Section 721 of the Defense Production Act of
1950 (as amended) or the rules or regulations promulgated thereunder (including 31 C.F.R. Part 800 and 31 C.F.R. part 801); provided,
however, that if the Purchaser is a “foreign person” for such purposes, it agrees that it will not (i) obtain
any control rights over the Company, including the ability to determine, direct, or decide important matters affecting the Company;
(ii) have access to any material nonpublic technical information in the possession of the company; (iii) obtain membership or observer
rights on the Board of Directors or the right to nominate an individual to a position on the Board of Directors; or (iv) have any
involvement, other than through voting of shares, in substantive decision making of the Company regarding the use, development,
acquisition or release of the Company’s technology.


 


(t) (For
ERISA plans only) The fiduciary of the Employee Retirement Income Security Act of 1974 (“ERISA”)
plan (the “Plan”) represents that such fiduciary has been informed of and understands the Company’s
investment objectives, policies and strategies, and that the decision to invest “plan assets” (as such term is defined
in ERISA) in the Company is consistent with the provisions of ERISA that require diversification of plan assets and impose other
fiduciary responsibilities. The Purchaser fiduciary or Plan (a) is responsible for the decision to invest in the Company; (b) is
independent of the Company or any of its Affiliates; (c) is qualified to make such investment decision; and (d) in making such
decision, the Purchaser fiduciary or Plan has not relied primarily on any advice or recommendation of the Company or any of its
Affiliates.


 




    25


     


    

 


(u) If
the Purchaser is a Covered Person, neither the Purchaser nor, to the Purchaser’s knowledge, any of its directors, executive
officers, other officers that may serve as a director or officer of any company in which it invests, general partners or managing
members is subject to any Disqualification Events, except for Disqualification Events covered by Rule 506(d)(2)(ii) or (iii) under
the Securities Act, and disclosed reasonably in advance of the applicable Closing in writing in reasonable detail to the Company.


 


(v) The
Purchaser understands that there are substantial restrictions on the transferability of the Shares and that the book-entry positions
representing the Shares shall bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed
against transfer of such certificates or other instruments):


 


THE SECURITIES REPRESENTED BY THIS
BOOK-ENTRY POSITION HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED
THEREUNDER (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY
INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT
THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION
EXISTS AND THE COMPANY RECEIVES AN OPINION OF COUNSEL, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT
SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR APPLICABLE STATE SECURITIES LAWS OR (3) SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT.


 


In addition, if the Purchaser is an Affiliate
of the Companys or book-entry positions evidencing the Shares issued to the Purchaser may bear a customary “Affiliates”
legend.


 


Any fees (with respect to the Company's
transfer agent (the "Transfer Agent"), counsel or otherwise) associated with the removal of such legend(s) shall be borne
by the Company.


 


The Company shall be obligated to
promptly reissue unlegended certificates upon the request of any holder thereof (x) at such time as the securities evidenced
by such certificates are sold pursuant to Rule 144 or another applicable exemption from the registration requirements of the
Securities Act has been satisfied or (y) at such time as a registration statement is available for the transfer of the
Shares. The Company is entitled to request from any holder requesting unlegended certificates under clause (x) of the
foregoing sentence a certificate of such holder reasonably acceptable to the Company confirming that the securities proposed
to be disposed of may lawfully be so disposed of without registration, qualification or legend.


 






    26


     


    

 


(w) If the Purchaser is
an individual, then the Purchaser resides in the state or province identified in the address of the Purchaser set forth on
such Purchaser’s Omnibus Signature Page to this Agreement; if the Purchaser is a partnership, corporation, limited
liability company or other entity, then the office or offices of the Purchaser in which its principal place of business is
identified in the address or addresses of the Purchaser set forth on such Purchaser’s Omnibus Signature Page to this
Agreement.


 


(x) The Purchaser
understands that the Company prior to the Merger was a “shell company” as defined in Rule 12b-2 under the Exchange
Act, and that upon filing with the SEC of the Super 8-K reporting the consummation of the Merger and related transactions and
the transactions contemplated by this Agreement, and otherwise containing “Form 10 information” discussed below, the
Company will reflect therein that it is no longer a shell company. Pursuant to Rule 144(i), securities issued by a current or
former shell company (that is, the Shares) that otherwise meet the holding period and other requirements of Rule 144 nevertheless
cannot be sold in reliance on Rule 144 until one year after the Company (a) is no longer a shell company; and (b) has filed
current “Form 10 information” (as defined in Rule 144(i)) with the SEC reflecting that it is no longer a shell company,
and provided that at the time of a proposed sale pursuant to Rule 144, the Company is subject to the reporting requirements of
Section 13 or 15(d) of the Exchange Act and has filed all reports and other materials required to be filed by Section 13 or 15(d)
of the Exchange Act, as applicable, during the preceding 12 months (or for such shorter period that the issuer was required to
file such reports and materials), other than Form 8-K reports. As a result, the restrictive legends on book-entry positions
for the Shares cannot be removed except in connection with an actual sale meeting the foregoing requirements or pursuant to an
effective registration statement.


 


(y) The
Purchaser, if and to the extent that it purchases Shares in any Subsequent Closing, represents that it (i)(A) has a substantive,
pre-existing relationship with the Company or (B) had direct contact by the Company or a Placement Agent outside of the Offering,
and (ii) did not contact the Company or a Placement Agent or become interested in the Offering as a result of reading or otherwise
being aware of the Super 8-K or any press release or any other public disclosure disclosing the terms of the Offering.


 


(z) To
effectuate the terms and provisions hereof, the Purchaser hereby appoints Stifel, Nicolaus & Company, Incorporated, as its
attorney-in-fact for the purpose of carrying out the provisions of the Escrow Agreement, including, without limitation, taking
any action on behalf of, or at the instruction of, the Purchaser and executing any release notices required under the Escrow Agreement
and taking any action and executing any instrument that Stifel, Nicolaus & Company, Incorporated, may deem necessary or advisable
(and lawful) to accomplish the purposes hereof, in each case, subject to and in accordance with the terms of this Agreement. All
lawful acts done under the foregoing authorization are hereby ratified and approved, and neither Stifel, Nicolaus & Company,
Incorporated, nor any designee nor agent thereof shall be liable for any acts of commission or omission, for any error of judgment,
for any mistake of fact or law except for acts of fraud, gross negligence or willful misconduct. This power of attorney, being
coupled with an interest, is irrevocable while the Escrow Agreement remains in effect.


 






    27


     


    

 


5. Conditions
to Company’s Obligations at Closing. The Company’s obligation to complete the sale and issuance of the Shares
and deliver the Shares to the Purchaser and to consummate the other transactions contemplated hereby at the Initial Closing and,
if applicable, a Subsequent Closing, shall be subject to the satisfaction or written waiver by the Company (in whole or in part)
of the following conditions, to the extent such condition can be waived, in its sole discretion, on or prior to the Initial Closing
Date and each Subsequent Closing Date, as applicable (provided, that any waiver by the Company of the condition set forth
in Section 5(f) shall require the prior written consent of the Purchaser):


 


(a) Receipt
of Payment. The Company shall have received payment, by certified or other bank check or by wire transfer of immediately available
funds, in the full amount of the Purchase Price for the number of Shares being purchased by the Purchaser at the Initial Closing
and, if applicable, a Subsequent Closing (less the amount of any Transaction Expenses, if applicable).


 


(b) Receipt
of Executed Transaction Documents. The Purchaser shall have executed and delivered to the Company the Omnibus Signature Page,
Accredited Investor Certification, the Investor Profile and the Anti-Money Laundering Information Form and the Selling Securityholder
Questionnaire (as defined in the Registration Rights Agreement).


 


(c) Representations
and Warranties. The representations and warranties made by the Purchaser in Section 4 hereof shall be true and correct in all
respects as of the date of this Agreement and as of such Closing Date with the same force and effect as if they had been made on
and as of such Closing Date (except to the extent any such representation or warranty expressly speaks as of an earlier date, in
which case such representation or warranty shall be true and correct in all respects as of such earlier date), except for the failure
of any such representation or warranty to be so true and correct as would not, individually or in the aggregate, have a material
adverse effect on the ability of the Purchaser to consummate the transactions contemplated hereby.


 


(d) Performance.
The Purchaser shall have performed or complied with in all material respects all obligations and covenants herein required to be
performed by the Purchaser on or prior to the applicable Closing.


 


(e) Effectiveness
of the Merger Transactions. The Merger and each of the other transactions contemplated by the Merger Agreement shall have been
effected and consummated.


 


(f) Minimum
Offering. In connection with the Initial Closing only, the Company shall have received proceeds from the Offering equal to
or greater than the Minimum Offering Amount (inclusive of the Minimum Insider Investment).


 


(g) Qualifications.
All Authorizations of, or notices to, any Governmental Authority that are required in connection with the transactions contemplated
by this Agreement, including the lawful issuance and sale of the Shares pursuant to this Agreement at each Closing except for Blue
Sky law permits and qualifications that may be properly obtained after such Closing and filing of a Notice of Exempt Offering of
Securities on Form D with the SEC under Regulation D which may be filed no later than 15 calendar days after the “date of
first sale” in the Offering.


 






    28


     


    

 


6. Conditions
to Purchaser’s Obligations at the applicable Closing. The Purchaser’s obligation to accept delivery of the
Shares and to pay for the Shares to be issued to the Purchaser hereunder at the Initial Closing and, if applicable, a Subsequent
Closing, and to consummate the other transactions contemplated hereby, shall be subject to the satisfaction or written waiver by
the Purchaser (in whole or in part) of the following conditions, to the extent such condition can be waived, in its sole discretion,
on or prior to the Initial Closing Date and each Subsequent Closing Date, as applicable:


 


(a) Representations
and Warranties. (i) The representations and warranties made by the Company (as modified by the disclosures on the Disclosure
Schedule or in the Draft Super 8-K (excluding any disclosures (whether contained under the heading “Risk Factors,”
in any “forward-looking statements” disclaimer or in any other section) to the extent they are cautionary, predictive
or forward-looking in nature) set forth in Sections 3(a), 3(b), 3(c), 3(d), 3(e), 3(h) and 3(i) hereof (collectively, the “Company
Fundamental Representations”) shall be true and correct in all respects as of the date of this Agreement and as of
such Closing Date with the same force and effect as if they had been made on and as of such Closing Date (except to the extent
any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall
be true and correct in all respects as of such earlier date) and (ii) the other representations and warranties made by the Company
in Section 3 shall be true and correct in all material respects (without giving effect to any limitation as to “materiality”
or “Material Adverse Effect” or similar qualifier) as of the date of this Agreement and as of such Closing Date with
the same force and effect as if they had been made on and as of such Closing Date (except to the extent any such representation
or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in
all material respects as of such earlier date).


 


(b) Performance.
The Company shall have performed or complied with in all material respects all obligations and covenants herein required to be
performed by it on or prior to the applicable Closing.


 


(c) Receipt
of Executed Transaction Documents. The Company shall have duly executed and delivered to the Placement Agents on behalf of
the Purchaser the Registration Rights Agreement and the Escrow Agreement.


 


(d) Effectiveness
of the Merger Transactions. The Merger and each of the other transactions contemplated by the Merger Agreement shall have been
effected and consummated.


 


(e) Minimum
Offering. In connection with the Initial Closing only, the Company shall have received proceeds from the Offering equal to
or greater than the Minimum Offering Amount (inclusive of the Minimum Insider Investment).


 


(f) Equity
Incentive Plan. The Board of Directors and the stockholders of the Company shall have duly adopted the EIP as described in
Recital B above.


 


(g) Certificate.
At each applicable Closing, an executive officer of the Company shall have duly executed and delivered or caused to be delivered
to the Placement Agents a certificate addressed to the Purchaser and the Placement Agents certifying as to the satisfaction of
the conditions set forth in Section 6(a) and Section 6(b) as of the applicable Closing Date


 


(h) Good
Standing. The Company and each of its Subsidiaries is a corporation or other business entity duly organized, validly existing,
and in good standing under the Laws of the jurisdiction of its formation.


 







    29


     


    

 


(i) Judgments.
No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy
court or judge, or any order of or by any Governmental Authority, shall have been issued, and no action or proceeding shall have
been instituted by any Governmental Authority, enjoining or preventing the consummation of the transactions contemplated hereby.


 


(j) Delivery
of Draft Super 8-K and Merger Agreement. The Company shall have delivered to the Purchaser, at least two (2) Business Days
prior to the Initial Closing, (A) the Draft Super 8-K (including all exhibits thereto), including audited and interim unaudited
financial statements of Augmedix and pro forma financial statements reflecting the Merger, all compliant with applicable SEC regulations
for inclusion under Items 2.01(f) and/or 5.01(a)(8) of SEC Form 8-K and (B) a substantially complete draft of the Merger Agreement
and each other material transaction document contemplated by or related to the Merger Agreement, including the disclosure schedules
thereto, each of which shall be reasonably acceptable the Purchaser.


 


(k) Legal
Opinion. Fenwick & West LLP, legal counsel for the Company, shall deliver an opinion addressed to the Purchaser and the
Placement Agents, dated as of the applicable Closing Date, in form and substance reasonably acceptable to the Placement Agents.


 


(l) Compliance
with Laws. The transactions contemplated by this Agreement and the other Transaction Documents, including the sale and issuance
of the Shares, shall be legally permitted by all Laws and regulations to which the Company is subject or which are otherwise applicable
to the transactions contemplated by the Transaction Documents.


 


(m) Qualifications.
All Authorizations of, or notices to, any Governmental Authority that are required in connection with the transactions contemplated
by this Agreement, including the lawful issuance and sale of the Shares pursuant to this Agreement at each Closing, shall have
been delivered or obtained and effective as of such Closing except for Blue Sky law permits and qualifications that may be properly
obtained after such Closing and filing of a Notice of Exempt Offering of Securities on Form D with the SEC under Regulation D which
may be filed no later than 15 calendar days after the “date of first sale” in the Offering.


 


(n) No
Material Adverse Effect. There shall have been no Material Adverse Effect that is continuing.


 






    30


     


    

 


7.
Indemnification.


 


(a) In
addition to the indemnity provided to the Purchaser in the applicable Registration Rights Agreement, the Company agrees to indemnify
and hold harmless the Purchaser and its Affiliates, and its and their respective directors, officers, stockholders, equityholders,
members, managers, partners, employees, attorneys, consultants, representatives and agents (and any other persons with a functionally
equivalent role of a person holding such titles notwithstanding a lack of such title or any other title), each person who controls
the Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers,
stockholders, equityholders, members, managers, partners, employees, attorneys, consultants, representatives and agents (and any
other persons with a functionally equivalent role of a person holding such titles notwithstanding a lack of such title or any other
title) of such controlling person (collectively, the “Purchaser Indemnitees”), from and against all losses,
liabilities, claims, damages, costs, fees, charges, Taxes, judgements, fines, penalties and expenses whatsoever (including, but
not limited to, amounts paid in settlement and any and all out-of-pocket expenses, including attorneys’ fees and expenses,
incurred in investigating, preparing or defending against any litigation commenced or threatened) (collectively, “Indemnified
Liabilities”) arising out of or relating to: (i) the inaccuracy, violation or breach of any of the Company’s
representations or warranties made in Section 3 of this Agreement; (ii) any breach or failure to perform by the Company of any
of its covenants and obligations contained herein or (iii) any Action brought or made against such Purchaser Indemnitee by a third
party (including for these purposes a derivative action brought on behalf of the Company) and arising out of, relating to or resulting
from (A) the execution, delivery, performance or enforcement of the Transaction Documents or the Merger Agreement or the transactions
contemplated hereby or thereby, including the issuance of the Shares and the Merger or (B) the status of the Purchaser as an investor
in the Company pursuant to the transactions contemplated hereby or by the other Transaction Documents. To the extent that the foregoing
undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment
and satisfaction of each of the Indemnified Liabilities that is permissible under applicable Law. The liability of the Company
under this paragraph shall not exceed the total Purchase Price paid by the Purchaser hereunder, except in the case of fraud.


 


(b) The
Company shall have the right to control the investigation and defense of any Action for which a Purchaser Indemnitee may be entitled
to indemnification hereunder with counsel reasonably satisfactory to such Purchaser Indemnitee, at the sole cost and expense of
the Company, upon written notice to the applicable Purchaser Indemnitee; provided, that (i) such notice contains confirmation
that the Company has agreed to indemnify the Purchaser Indemnitee (subject to the limitations on indemnification set forth herein)
for the Indemnified Liabilities arising out of, relating to or resulting from such Action and (ii) the Company shall not be entitled
to assume or control the investigation and defense, if (A) such claim seeks non-monetary, equitable or injunctive relief or alleges
any violation of criminal Law or (B) the Indemnitor is also a party and the Indemnitee determines in good faith after consultation
with counsel that there may be one or more legal defenses available to such Indemnitee that are different or additional to those
available to the Indemnitor. If the Company assumes the investigation and defense of such Action in accordance herewith, the Purchaser
Indemnitee may retain separate co-counsel at its sole cost and expense and participate in the investigation and defense of such
Action.


 






    31


     


    

 


(c) Notwithstanding
anything to the contrary herein, without the prior written consent of the Purchaser Indemnitee, the Company shall not, and shall
not cause or permit any of its Subsidiaries or its or their respective Related Parties to, negotiate, consent to or enter into
any settlement, or consent to the entry of any judgment, with respect to any Action for which such Purchaser Indemnitee may be
entitled to indemnification hereunder, unless such settlement (i) includes an unconditional release of such Purchaser Indemnitee
from all liability arising out of such proceeding, (ii) does not require any admission of wrongdoing by any Purchaser Indemnitee,
and (iii) does not obligate or require any Purchaser Indemnitee to take, or refrain from taking, any action.


 


(d) The
Purchaser acknowledges on behalf of itself and each Purchaser Indemnitee that, other than (i) for Actions seeking specific performance
of the obligations under this Agreement; (ii) if applicable, for Actions to recover any Transaction Expenses or (iii) in the case
of a breach or violation of this Agreement by the Company which has resulted from either (A) intentional fraud or (B) a deliberate
act or failure to act with actual knowledge that the act or failure to act constituted or would result in a breach or violation,
in each case, the sole and exclusive remedy of the Purchaser and the Purchaser Indemnitees with respect to any and all claims relating
to this Agreement shall be pursuant to the indemnification provisions (including the limitations thereof) set forth in this Section
7.


 


8. Revocability;
Binding Effect. The subscription hereunder may be revoked, in whole or in part, prior to the Initial Closing or any Subsequent
Closing, as applicable, in the sole discretion of the Purchaser, for any reason or no reason, provided that written notice of revocation
is sent and is received by the Company or a Placement Agent at least two (2) Business Days prior to the Initial Closing Date or
the applicable Subsequent Closing Date. The Purchaser hereby acknowledges and agrees that this Agreement shall survive the death
or disability of the Purchaser and shall be binding upon and inure to the benefit of the parties and their heirs, executors, administrators,
successors, legal representatives and permitted assigns. If the Purchaser is more than one person, the obligations of the Purchaser
hereunder shall be joint and several and the agreements, representations, warranties and acknowledgments herein shall be deemed
to be made by and be binding upon each such person and such person’s heirs, executors, administrators, successors, legal
representatives and permitted assigns.


 


9.
Miscellaneous.


 


(a) Modification.
This Agreement shall not be amended, modified or waived except by an instrument in writing signed by the Company and the holders
of at least a majority of the Shares and Other Shares; provided that this Agreement may not be amended and the observance of any
term hereof may not be waived with respect to any Purchaser without the written consent of such Purchaser if such amendment or
waiver on its face materially and adversely affects the rights of such Purchaser under this Agreement in a manner that is different
than the other Purchasers. Any amendment, modification or waiver effected in accordance with this Section 9(a) shall be binding
upon the Purchaser and each transferee of the Shares, each future holder of all such Shares, and the Company, its successors and
assigns.


 


(b) Third-Party
Beneficiary. The Placement Agents shall be express third party beneficiaries of the representations and warranties of
the Company and the Purchaser included in Sections 3 and 4 of this Agreement. This Agreement is intended for the benefit of the
parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof
be enforced by, any other person, except as otherwise set forth in Section 7 and this Section 9(b).


 






    32


     


    

 


(c) Notices.
Any notice, consents, waivers or other communication required or permitted to be given hereunder shall be in writing and will be
deemed to have been delivered: (i) upon receipt, when personally delivered; (ii) upon receipt when sent by certified mail, return
receipt requested, postage prepaid; (iii) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically
or electronically generated and kept on file by the sending party; (iv) when sent, if by e-mail (provided that such sent e-mail
is kept on file (whether electronically or otherwise) by the sending party and the sending party does not receive an automatically
generated message from the recipient’s e- mail server that such e-mail could not be delivered to such recipient); or (v)
one (1) Business Day after deposit with a nationally recognized overnight courier service with next day delivery specified, in
each case, properly addressed to the party to receive the same. The addresses, facsimile numbers and email addresses for such communications
shall be:


 


(i)
if to the Company, at


 


Malo Holdings Corporation (to be renamed Augmedix,
Inc.)


2255 Glades Road, Suite 324A


Boca Raton, Florida 33431


Attention: [*]


Email: [*]


 


with copies (which shall not constitute notice) to:


 


Sichenzia Ross Ference LLP


1185 Avenue of the Americas


New York, NY 10036


Attention: [*]


Facsimile: [*]


E-mail: [*]


 


and


 


Fenwick & West LLP


902 Broadway


New York, NY 10010


Attention: [*]


Email: [*]


 


or


 


(ii)
if to the Purchasers, at the address set forth on each such Omnibus Signature Page hereof


 


(or, in either case, to such other address as the party shall
have furnished in writing in accordance with the provisions of this Section).


 


(d) Assignability.
This Agreement and the rights, interests and obligations hereunder are not transferable or assignable by the Purchaser (including,
for the avoidance of doubt, any Significant Purchaser), other than an assignment of the rights, interests and obligations hereunder
in connection with any transfer of the Shares by a Purchaser to a Permitted Assignee (as such term is defined in the Registration
Rights Agreement). For the avoidance of doubt, nothing in this Section 9(d) is intended to, or shall have the effect of, restricting
or otherwise impairing any transfer of the Shares by the Purchaser.


 






    33


     


    

 


(e) Applicable
Law. This Agreement and the other Transaction Documents and the transactions contemplated hereby and thereby shall be
governed by and construed in accordance with the Laws of the State of New York, without reference to the principles thereof relating
to the conflict of Laws. Any litigation based hereon, or arising out of, under or in connection with, this Agreement or any other
Transaction Document or the transactions contemplated hereby or thereby shall be brought and maintained exclusively in the United
States District Court for the Southern District of New York or the circuit court for New York County, New York. Each party irrevocably
consents to the service of process of any of the aforementioned courts in any such suit, action or proceeding by the mailing of
copies thereof by registered or certified mail, postage prepaid, return receipt requested, to such party's address set forth in
Section 9(c), such service to become effective ten (10) days after such mailing.


 


(f) WAIVER
OF JURY TRIAL. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION OR COUNTERCLAIM
(WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT, THE
TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY OR THE ACTIONS OF SUCH PARTY IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT
HEREOF.


 


(g) Form
D; Blue Sky Qualification. The Company agrees to timely file a Form D with respect to the Shares and to provide a copy thereof,
promptly upon request of the Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary
in order to obtain an exemption for, or to qualify the Shares for, sale to the Purchaser at such Closing under applicable securities
or “Blue Sky” laws of the states of the United States, and shall provide evidence of such actions promptly upon request
of the Purchaser.


 


(h) Use
of Pronouns. All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine,
neuter, singular or plural as the identity of the person or persons referred to may require.


 


(i) Securities
Law Disclosure; Publicity. By 9:00 a.m., New York City time, on the trading day immediately following the Initial Closing,
the Company shall issue a press release (the “Press Release”) disclosing all material terms of the Offering.
The Company will also file the Super 8-K (and including as exhibits to such Super 8-K, the material Transaction Documents (including,
without limitation, this Agreement and the Registration Rights Agreement)) as soon as practicable following the closing date of
the Merger but in no event more than four (4) Business Days following the closing date of the Merger. Notwithstanding the foregoing,
the Company shall not publicly disclose the name of the Purchaser or an Affiliate of the Purchaser, or include the name of the
Purchaser or an Affiliate of the Purchaser in any press release or filing with the SEC (other than the Registration Statement)
or any regulatory agency or principal trading market, without the prior written consent of the Purchaser, except (i) as required
by federal securities Law in connection with (A) any registration statement contemplated by the Registration Rights Agreement and
(B) the filing of final Transaction Documents with the SEC or (ii) to the extent such disclosure is required by applicable Law,
request of the staff of the SEC or of any regulatory agency or principal trading market regulations, in which case the Company
shall provide the Purchaser with prior written notice of such disclosure permitted under this sub-clause (ii). From and after the
filing of the Super 8-K, no Purchaser shall be in possession of any material, non-public information received from the Company
or any of its respective officers, directors, employees or agents or any other person acting on its behalf in connection with the
Offering that is not disclosed in the Super 8-K unless the Purchaser shall have executed a written agreement with the Company regarding
the confidentiality and use of such information or is otherwise subject to confidentiality restrictions. The Purchaser, severally
and not jointly with the Other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are
publicly disclosed by the Company as described in this Section 9(i), the Purchaser will maintain the confidentiality of all disclosures
made to it in connection with such transactions (including the existence and terms of such transactions), except to the extent
such disclosure (x) is made to the Purchaser Parties in connection with the transactions contemplated hereby or (y) is required
by applicable Law. In addition, the Purchaser acknowledges that it is aware that United States securities laws may restrict persons
who have material, non-public information about a company from purchasing or selling any securities of such company while in possession
of such information. The provisions of this Section 9(i) are in addition to and not in replacement of any other confidentiality
agreement, if any, between the Company and the Purchaser.


 






    34


     


    

 


(j) Entire
Agreement. This Agreement, together with the Registration Rights Agreement and each other Transaction Document, and all exhibits,
schedules and attachments hereto and thereto, including the Disclosure Schedule and any confidentiality agreement between the Purchaser
and the Company, constitute the entire agreement between the Purchaser and the Company with respect to the Offering and supersede
all prior oral or written agreements and understandings, if any, relating to the subject matter hereof.


 


(k) Share
Certificates. If the Shares are certificated and any certificate or instrument evidencing any Shares is mutilated, lost, stolen
or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or
in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company and the Company’s transfer agent of such loss, theft or destruction and the execution by the holder thereof
of a customary lost certificate affidavit of that fact and an agreement to indemnify and hold harmless the Company and its transfer
agent for any losses in connection therewith or, if required by such transfer agent, a bond in such form and amount as is required
by the transfer agent. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs associated with the issuance of such replacement Shares. If a replacement certificate or instrument evidencing
any Shares is requested due to a mutilation thereof, the Company may require delivery of such mutilated certificate or instrument
as a condition precedent to any issuance of a replacement.


 


(l) Expenses.
Each of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or
others engaged by such party) in connection with this Agreement and the transactions contemplated hereby, whether or not the transactions
contemplated hereby are consummated. Without limiting the foregoing, the Company shall pay all Transfer Agent fees, stamp taxes
and other Taxes and duties levied in connection with the sale and issuance of the Offering, and the Company shall file all necessary
Tax Returns and other documentation with respect to such fees, Taxes and duties, and the Company shall pay all fees and expenses
of its counsel in connection with the issuance of any opinion required by Section 6(k) above and of any opinion to the Transfer
Agent for the removal of any legend on the Shares.


 


(m) Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together
shall constitute one and the same instrument. The exchange of copies of this Agreement and of signature pages that contain copies
of an executed signature page such as in .pdf format shall constitute effective execution and delivery of this Agreement as to
the parties and may be used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by facsimile
or by e-mail of a document in .pdf format shall be deemed to be their original signatures for all purposes.


 







    35


     


    

 


(n) Severability.
Each provision of this Agreement shall be considered separable and, if for any reason any provision or provisions hereof are determined
to be invalid or contrary to applicable Law, such invalid or contrary provision shall be replaced with a valid provision that as
closely as possible reflects the parties’ intent with respect thereto, and invalidity or illegality shall not impair the
operation of or affect the remaining portions of this Agreement.


 


(o) Headings.
Paragraph titles are for descriptive purposes only and shall not control or alter the meaning of this Agreement as set forth in
the text.


 


(p) Multiple
Closings. The Purchaser understands and acknowledges that there may be multiple Closings for the Offering.


 


(q) Additional
Information; Further Assurances. The Purchaser hereby agrees to furnish the Company such other information as the Company may
reasonably request prior to the applicable Closing with respect to its subscription hereunder. Each party hereto shall do and perform,
or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates,
instruments and documents, as the other party hereto may reasonably request in order to effect the transactions contemplated hereby
and to accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.


 


(r) Survival.
The parties, agree that, if the Closing occurs, the representations and warranties of the Company and each Purchaser contained
in this Agreement shall survive the execution and delivery of this Agreement for a period of one (1) year from the Initial Closing
Date and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of the
Purchaser or the Company. The covenants and agreements contained in this Agreement (including the covenants and agreements set
forth in Section 7 hereof) shall survive the Closing and delivery of the Shares in accordance with their terms or, if no term is
specified, such covenants and agreements shall survive indefinitely. Notwithstanding anything herein to the contrary, in no event
shall the Purchaser have any liability to the Company or to any other person in connection with the Offering other than pursuant
to this Agreement.


 


(s) Omnibus
Signature Page. This Agreement is intended to be read and construed in conjunction with the Registration Rights Agreement.
Accordingly, pursuant to the terms and conditions of this Agreement and the Registration Rights Agreement, it is hereby agreed
that the execution by the Purchaser of this Agreement, in the place set forth on the Omnibus Signature Page below, shall constitute
agreement to be bound by the terms and conditions hereof and the terms and conditions of the Registration Rights Agreement, with
the same effect as if each of such separate but related agreement were separately signed.


 


(t) Public
Disclosure. Neither the Purchaser nor any officer, manager, director, member, partner, stockholder, employee, Affiliate,
Affiliated person or entity of the Purchaser shall make or issue any press releases or otherwise make any public statements or
make any disclosures to any third person or entity with respect to the transactions contemplated herein and will not make or issue
any press releases or otherwise make any public statements of any nature whatsoever with respect to the Company without the Company’s
express prior approval (which may be withheld in the Company’s sole discretion), except to the extent such disclosure is
required by Law, request of the staff of the SEC or of any regulatory agency or principal trading market regulations.


 






    36


     


    

 


(u) Potential
Conflicts. The Placement Agents, their sub-agents, legal counsel to the Company, the Placement Agents or Augmedix and/or
their respective Affiliates, principals, representatives or employees may now or hereafter own shares of the Company.


 


(v) Independent
Nature of the Purchaser’s Obligations and Rights. For avoidance of doubt, the obligations of the Purchaser under this
Agreement, the other Transaction Documents and any other agreements delivered in connection herewith are several and not joint
with the obligations of any Other Purchaser in connection with the Offering, and the Purchaser shall not be responsible in any
way for the performance of the obligations of any Other Purchaser in connection with the Offering. Nothing contained herein and
no action taken by the Purchaser shall be deemed to constitute the Purchaser as a partnership, an association, a joint venture,
or any other kind of entity, or create a presumption that the Purchaser is in any way acting in concert or as a group with any
Other Purchaser in connection with the Offering with respect to such obligations or the transactions contemplated by this Agreement
or any other Transaction Document or any Other Subscription Agreement. Except as specifically set forth herein, the Purchaser shall
be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement,
and it shall not be necessary for any other party to be joined as an additional party in any proceeding for such purpose.


 


(w) Waiver
of Conflicts. Each party to this Agreement acknowledges that each of Sichenzia Ross Ference LLP, counsel to the Company
prior to the Merger, Fenwick & West LLP, counsel to Augmedix, and the Company post-Merger, Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C., counsel to the Placement Agents, may have in the past performed and may continue to or in the future perform legal
services for certain of the Purchasers in matters unrelated to the transactions described in this Agreement, including financings
and other matters. Accordingly, each party to this Agreement hereby (a) acknowledges that they have had an opportunity to ask for
information relevant to this disclosure; (b) acknowledges that Sichenzia Ross Ference LLP, Fenwick & West LLP and Mintz, Levin,
Cohn, Ferris, Glovsky and Popeo, P.C. represented the Company, Augmedix and the Placement Agents, respectively, in the transaction
contemplated by this Agreement and has not represented any individual Purchaser in connection with such transaction; and (c) gives
its informed consent to Sichenzia Ross Ference LLP’s, Fenwick & West LLP’s and Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C.’s representation of certain of the Purchasers in such unrelated matters and to Sichenzia Ross Ference LLP’s,
Fenwick & West LLP’s and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.’s representation of the Company, Augmedix
and the Placement Agents, respectively, in connection with this Agreement and the transactions contemplated hereby. Further, each
party to this Agreement hereby acknowledges that Fenwick & West LLP anticipates that it will advise the Company following the
Merger.


 


(x) Adjustments.
In the event of any stock split, subdivision, dividend or distribution payable in shares of Common Stock (or other securities or
rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), combination
or other similar recapitalization or event occurring after the date hereof, each reference in any Transaction Document to a number
of Shares or the Per Share Purchase Price shall be deemed to be amended to appropriately account for such event.


 




    37


     


    

 


(y) Remedies.
The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not
performed by them in accordance with the terms hereof and that each party hereto may be entitled to seek protective orders, injunctive
relief and other remedies available at Law or in equity (including, without limitation, seeking specific performance or rescission
of purchases, sales and other transfers). The parties hereto agree not to raise any objections to the availability of the equitable
remedy of specific performance to prevent or restrain breaches of this Agreement by the Purchaser or the Company, as applicable,
and to specifically enforce the terms and provisions of this Agreement to prevent breaches or threatened breaches of, or to enforce
compliance with, the respective covenants and obligations of the Purchaser and the Company, as applicable, under this Agreement
all in accordance with the terms of this Section 9(z). Neither the Purchaser nor the Company, as applicable, shall be required
to provide any bond or other security in connection with seeking an injunction or injunctions to prevent breaches of this Agreement
and to enforce specifically the terms and provisions of this Agreement, all in accordance with the terms of this Section 9(z).


 


(z) Recourse.
Notwithstanding anything that may be expressed or implied in this Agreement or in any other Transaction Document, and notwithstanding
the fact that the Purchaser may be partnerships or limited liability companies, the Company hereto covenants, agrees and acknowledges
that no recourse under this Agreement or any Transaction Document shall be had against any the Purchaser’s future, present
or former Affiliates, or the Purchaser’s or its Affiliates’ respective future, present or former officers, directors,
managers, employees, partners, equityholders, controlling persons, members, agents, attorneys, representatives, successors or permitted
assigns (the “Purchaser Parties”) (other than the Purchaser and its successors and Permitted Assignees
under this Agreement), whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any
applicable Law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on
or otherwise be incurred by any of the Purchaser Parties, as such, for any obligation or liability of any party under this Agreement
or any other Transaction Document for any claim based on, in respect of or by reason of such obligations or liabilities or their
creation; provided, however, nothing in this Section 9(aa) shall relieve or otherwise limit the liability of the
Purchaser or any of its successors or Permitted Assignees, for any breach or violation of its obligations under such agreements,
documents or instruments. The liability limitation provision in this Section 9(aa) shall survive termination of this Agreement.


 


(aa) Use of Proceeds. The Company
shall use the net proceeds from the Offering for capital expenditures and for working capital and other general corporate purposes.


 


[Signature page follows.]


 






    38


     


    

 


IN WITNESS WHEREOF, the Company has duly executed this Agreement
as of the                          day of     , 2020.


  


	 	MALO HOLDINGS CORPORATION
	 	(to be renamed “Augmedix, Inc.”)
	 	 	 
	 	By:	                    
	 	Name:
	 	Title:
	 	 
	 	AUGMEDIX, INC.
	 	 	 
	 	By:	 
	 	Name:
	 	Title:


 






     


     


    

 


How to subscribe for Shares in the private
offering of MALO HOLDINGS CORPORATION


 


		1.	Date and Fill in the number of Shares being purchased and complete and sign the Omnibus Signature Page.



 


		2.	Unless otherwise instructed by your broker representative or advisor:



 


		●	Initial the Accredited Investor Certification in the appropriate place or places.



 


		●	Complete and sign the Investor Profile.



 


		●	Complete and sign the Anti-Money Laundering Information Form.



 


		3.	Complete and sign the Selling Securityholder Questionnaire



 


		4.	Fax or email all forms and then send all signed original documents to:



 


Stifel, Nicolaus & Co., Inc.


One Montgomery Street, Suite 3700


San Francisco, CA 94104


		Attn:	[*]



		E-mail Address:	[*]



		Office Number:	[*]



		Mobile Number:	[*]



 


		5.	If you are paying the Purchase Price by check, a certified or other bank check for
the exact dollar amount of the Purchase Price for the number of Shares you are purchasing should be made payable to the order of
“Delaware Trust Company, as Escrow Agent for Augmedix, Inc., Acct.
# 79-4244” and should be sent directly to Delaware Trust Company, 251 Little Falls Drive, Wilmington, Delaware 19808,
Wilmington, DE 19808, Attn: Alan R. Halpern.






 


Checks take up to 5 business days to clear. A
check must be received by the Escrow Agent at least 6 business days before the closing date.


 


		6.	If you are paying the Purchase Price by wire transfer, you should send a wire transfer for the exact dollar amount
of the Purchase Price for the number of Shares you are purchasing according to the following instructions:



 


	Bank:	[*]
	 	[*]
	 	[*]
	ABA Routing #:	[*]
	SWIFT CODE:	[*]
	Account Name:	[*]
	Account #:	[*]
	Reference:	[*]
	 	[INSERT PURCHASER’S NAME]”
	Delaware Trust Contact:	[*]


 


Thank you for your interest.


 






     


     


    

 


MALO HOLDINGS CORPORATION (to be renamed
“Augmedix, Inc.”)


OMNIBUS SIGNATURE PAGE TO


SUBSCRIPTION AGREEMENT AND REGISTRATION
RIGHTS AGREEMENT


 


The
undersigned, desiring to: (i) enter into the Subscription Agreement, dated as of                           , 2020 (the “Subscription
Agreement”), between the undersigned, Malo Holdings Corporation (to be renamed “Augmedix,
Inc.”), a Delaware corporation (the “Company”), and the other parties thereto, in or
substantially in the form furnished to the undersigned, (ii) enter into the Registration Rights Agreement (the
“Registration Rights Agreement”), among the undersigned, the Company and the other parties thereto,
in or substantially in the form furnished to the undersigned, and (iii) purchase the Shares of the Company’s securities
as set forth in the Subscription Agreement and below, hereby agrees to purchase such Shares from the Company and further
agrees to join the Subscription Agreement and the Registration Rights Agreement as a party thereto, with all the rights and
privileges appertaining thereto, and to be bound in all respects by the terms and conditions thereof. The undersigned
specifically acknowledges having read the representations section in the Subscription Agreement entitled
“Representations and Warranties of the Purchaser” and hereby represents that the statements contained therein are
complete and accurate with respect to the undersigned as a Purchaser.


 


IN WITNESS WHEREOF, the Purchaser hereby executes the Subscription
Agreement and the Registration Rights Agreement.


 


	Dated:	          	, 2020


 





	 	×	 	$3.00		=	$	 
	Number of Shares	 	Purchase Price per Share	 	Total Purchase Price	 


 


	PURCHASER (individual)	 	PURCHASER (entity)
	 	 	 
	 	 	 
	Signature	 	Name of Entity
	 	 		                
	 	 	By:	 
	Print Name	 	 	Signature


 


	 	 	Print Name:	        





	Signature (if Joint Tenants or Tenants in Common)	 	Title:	        
	 	 	 	 
	Address of Principal Residence:	 	Address of Executive Offices:
	 	 	 
	 	 	 
	 	 	 


 


	Social Security Number(s):	 	IRS Tax Identification Number:
	 	 	 
	 	 	 
	Telephone Number:	 	Telephone Number:
	 	 	 
	 	 	 
	Facsimile Number:	 	Facsimile Number:
	 	 	 
	 	 	 
	E-mail Address:	 	E-mail Address:
	 	 	 


 





 






		1	Will reflect the Closing Date. Not to be completed by Subscriber.



 




     


     


    

 


MALO HOLDINGS CORPORATION (TO BE
RENAMED “AUGMEDIX, INC.”)


ACCREDITED INVESTOR CERTIFICATION


For Individual Investors Only


(all Individual Investors must INITIAL
where appropriate):


 


	Initial	______	I have
    a net worth of at least US$1 million either individually or through aggregating my individual holdings and those in which
    I have a joint, community property or other similar shared ownership interest with my spouse. (For purposes of calculating
    your net worth under this paragraph, (a) your primary residence shall not be included as an asset; (b) indebtedness
    secured by your primary residence, up to the estimated fair market value of your primary residence at the time of your purchase
    of the securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the
    time of your purchase of the securities exceeds the amount outstanding 60 days before such time, other than as a result of
    the acquisition of your primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness
    that is secured by your primary residence in excess of the estimated fair market value of your primary residence at the time
    of your purchase of the securities shall be included as a liability.)





	Initial	______	I have had an annual gross income for the past two years of at least US$200,000 (or US$300,000 jointly with my spouse) and expect my income (or joint income, as appropriate) to reach the same level in the current year.
	Initial	______	I am a director or executive officer of the Augmedix, Inc. or Malo Holdings Corporation


 


For Non-Individual Investors (Entities)


(all Non-Individual Investors must INITIAL
where appropriate):


 


	Initial	______	The investor certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by persons who meet at least one of the criteria for Individual Investors set forth above (in which case each such person must complete the Accreditor Investor Certification for Individuals above as well the remainder of this questionnaire).
	Initial	______	The investor certifies that it is a partnership, corporation, limited liability company or business trust that has total assets of at least US$5 million and was not formed for the purpose of investing the Company.
	Initial	______	The investor certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in ERISA § 3(21)) that is a bank, savings and loan association, insurance company or registered investment advisor.
	Initial	______	The investor certifies that it is an employee benefit plan whose total assets exceed US$5,000,000 as of the date of this Agreement.
	Initial	______	The undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who meet at least one of the criteria for Individual Investors.
	Initial	______	The investor certifies that it is a U.S. bank as defined in Section 3(a)(2) of the Securities Act, or any U.S. savings and loan association or other similar U.S. institution as defined in Section 3(a)(5) of the Securities Act acting in its individual or fiduciary capacity.
	Initial	______	The undersigned certifies that it is a broker-dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934.
	Initial	______	The investor certifies that it is an organization described in Section 501(c)(3) of the Internal Revenue Code with total assets exceeding US$5,000,000 and not formed for the specific purpose of investing in the Company.
	Initial	______	The investor certifies that it is a trust with total assets of at least US$5,000,000, not formed for the specific purpose of investing in the Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of the prospective investment.
	Initial	______	The investor certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of US$5,000,000.
	Initial	______	The investor certifies that it is an insurance company as defined in Section 2(a)(13) of the Securities Act of 1933, or a registered investment company.



 



     


     


    

MALO HOLDINGS CORPORATION (TO BE RENAMED
“AUGMEDIX, INC.”)


 


Investor Profile


(Must be completed by Investor)


 


Section A - Personal Investor Information


 


	Investor Name(s): 	 


 


	Individual executing Profile or Trustee: 	 


 


	Social Security Numbers / Federal I.D. Number: 	 


 


	Date of Birth:	 	 	Marital Status:	 





	Joint Party Date of Birth:	 	 	Investment Experience (Years):	               




	Annual Income:	 	 	Liquid Net Worth:	 




	Net Worth*:	 	 	 


 


	Tax Bracket:	_____ 15% or below	_____ 25% - 27.5%	_____ Over 27.5%


 


	Home Street Address:	 


 


	Home City, State & Zip Code:	 


 


	Home Phone:	 	Home Fax: 	 	Home Email: 	 


 


	Employer:	 


 


	Employer Street Address:	 


 


	Employer City, State & Zip Code:	 


 


	Bus. Phone:	 	Bus. Fax: 	 	Bus. Email: 	 


 


	Nature of Business (type of sector or industry):	 	Title/Position: 	 


 


	Outside Broker/Dealer:	    


 


Section B –Form of Payment –
Check or Wire Transfer


 


____ Check payable to Delaware Trust Company, as Escrow Agent
for Augmedix, Inc., Acct #79-4244


____ Wire funds from my outside account according to instructions
of the Subscription Agreement. 


____ The funds for this investment are rolled over, tax deferred
from __________ within the allowed 60 day window.


 


Please check if you are a FINRA member or affiliate of a FINRA
member firm: ____


 


 


	 	 	 
	Investor Signature	 	Date


 


		*	For purposes of calculating your net worth in this form, (a) your primary residence shall
not be included as an asset; (b) indebtedness secured by your primary residence, up to the estimated fair market value of your
primary residence at the time of your purchase of the securities, shall not be included as a liability (except that if the amount
of such indebtedness outstanding at the time of your purchase of the securities exceeds the amount outstanding 60 days before such
time, other than as a result of the acquisition of your primary residence, the amount of such excess shall be included as a liability);
and (c) indebtedness that is secured by your primary residence in excess of the estimated fair market value of your primary residence
at the time of your purchase of the securities shall be included as a liability.



 




     


     


    

 


ANTI MONEY LAUNDERING REQUIREMENTS


 


The USA PATRIOT Act


 


The USA PATRIOT Act is designed to detect,
deter, and punish terrorists in the United States and abroad. The Act imposes new anti-money laundering requirements on brokerage
firms and financial institutions. Since April 24, 2002 all brokerage firms have been required to have new, comprehensive anti-money
laundering programs.


 


To help you understand these efforts, we
want to provide you with some information about money laundering and our steps to implement the USA PATRIOT Act.


 


What is money laundering?


 


Money laundering is the process of disguising
illegally obtained money so that the funds appear to come from legitimate sources or activities. Money laundering occurs in connection
with a wide variety of crimes, including illegal arms sales, drug trafficking, robbery, fraud, racketeering, and terrorism.


 


How big is the problem and why is it important?


 


The use of the U.S. financial system by
criminals to facilitate terrorism or other crimes could well taint our financial markets. According to the U.S. State Department,
one recent estimate puts the amount of worldwide money laundering activity at $1 trillion a year.


 


What are we required to do to eliminate money laundering?


 


Under rules required by the USA PATRIOT
Act, our anti-money laundering program must designate a special compliance officer, set up employee training, conduct independent
audits, and establish policies and procedures to detect and report suspicious transaction and ensure compliance with such laws.
As part of our required program, we may ask you to provide various identification documents or other information. Until you provide
the information or documents we need, we may not be able to effect any transactions for you.


 




     


     


    

ANTI-MONEY LAUNDERING INFORMATION FORM


 


The following is required in accordance
with the AML provision of the USA PATRIOT ACT.


 


(Please fill out and return with requested
documentation.)


 


	INVESTOR NAME:	 	 
	 	 	 
	LEGAL ADDRESS:	 	 
	 	 	 
	 	 	 
	SSN# or TAX ID# 	 	 
	OF INVESTOR:	 	 
	 	 	 
	YEARLY INCOME:	 	 
	 	 	 
	NET WORTH:	 	 *


 


* For
purposes of calculating your net worth in this form, (a) your primary residence shall not be included as an asset; (b) indebtedness
secured by your primary residence, up to the estimated fair market value of your primary residence at the time of your purchase
of the securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time
of your purchase of the securities exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition
of your primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness that is secured by
your primary residence in excess of the estimated fair market value of your primary residence at the time of your purchase of the
securities shall be included as a liability.


 


	INVESTMENT OBJECTIVE(S) FOR ALL INVESTORS: 	 	 


 


	ADDRESS OF BUSINESS OR OF EMPLOYER:  	 	 
	 	 	 
	 	 	 	 


 


	FOR INVESTORS WHO ARE INDIVIDUALS: AGE:  	 	 


 


	FOR INVESTORS WHO ARE INDIVIDUALS: OCCUPATION:  	 	 


 


	FOR INVESTORS WHO ARE ENTITIES: Business Sector/Industry): 	 	 


 


BANK SECRECY ACT (BSA) REQUIREMENT


 


Identify and complete for each of the 25% or more beneficial
owner(s) of the entity as defined below:1


 


	Name: 	 	Percent of Ownership: 	 	 


 


	Home Address (No PO Box): 	 	 


 


	Phone Number: 	 	Email Address: 	 	 


 


	Title (if applicable):  	 	 


 


	Social Security Number: 	 	Date of Birth: 	 	 


 


Please provide documents to verify the identity of the beneficial
owner(s), including a current valid issued government id for each beneficial owner identified above.


 





 



 


		1	Beneficial Owner: each individual, if any, who directly or indirectly, through any contract,
arrangement, understanding, relationship or otherwise owns 25% or more of the equity interests of a legal entity investor: (A)
a single individual with significant responsibility to control, manage or direct a legal entity investor, including, (i) an executive
officer or senior manager (e.g. Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, Managing Member, General
Partner, President, Vice President or Treasurer) or (ii) any other individual who regularly performs similar functions or (B) if
a trust owns directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, 25% or more of
the equity interests of a legal entity investor, the beneficial owner shall mean the trustee. It is the ultimate beneficial owner(s)
that must be identified and not nominees.



 




     


     


    

 


IDENTIFICATION & DOCUMENTATION
AND SOURCE OF FUNDS:


 


		1.	Please submit a copy of non-expired identification for the authorized
signatory(ies) on the investment documents, showing name, date of birth, address and signature. The address shown on the identification
document MUST match the Investor’s address shown on the Investor Signature Page.






 


	Current Driver’s License	 or	Valid Passport

(Circle one or more)	or	Identity Card


 


		2.	If the Investor is a corporation, limited liability company, trust or other type of entity, please
submit the following requisite documents: (i) Articles of Incorporation, By-Laws, Certificate of Formation, Operating Agreement,
Trust or other similar documents for the type of entity; and (ii) Corporate Resolution or power of attorney or other similar document
granting authority to signatory(ies) and designating that they are permitted to make the proposed investment.



 


		3.	Please advise where the funds were derived from to make the proposed investment:



 


	Investments	Savings	Proceeds of Sale	Other ________


(Circle one or more)


 


	Signature:	 	 




	Print Name:	 	 




	Title (if applicable):	 	 




	Date:	 	 


 






     


     


    

 


DISCLOSURE SCHEDULE


 


[____________], 2020


 




     


     


    

 


EXHIBIT A


 


Form of Registration Rights Agreement